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Ovarian cancer is the most lethal gynecologic cancer due to its typical late stage 
diagnosis, after metastasis has begun. The lack of a treatment without harmful side 
effects and ultimately, a cure, is an increasingly significant clinical burden. Although 
immune cells are heavily present within ovarian cancer tumors and the surrounding 
microenvironment, late stage diagnoses result in less than a 25% patient 5-year survival 
rate. Current standard of care includes chemotherapy, radiation, and surgery but exhibits 
limited success and has complications due to side effects. Moreover, although over 80% 
of ovarian cancer patients respond favorably to treatment initially, the majority of these 
patients will ultimately experience cancer recurrence, which can eventually lead to 
chemotherapy-resistance. Consequently, there is an unmet need for innovative treatment 
strategies – immunotherapy is of particular interest as there is an increased understanding 
about the frequently immunosuppressive nature of the tumor microenvironment; 
advances in immunotherapeutic strategies have even yielded curative results in some 
patients. 
 Tumor microenvironments are made up of cancer cells, resident healthy tissue, 
supporting stromal cells, and immune cells. Cues from these cells interplay in a highly 
coordinated fashion to drive pro-cancer or anti-cancer immune responses and thus govern 
the tumor microenvironment and determines whether cancer cells proliferate or die. 
Notably, resident tumor cells frequently express or secrete immune-inhibitory signals that 
work to suppress immune cell recognition and function. Thus, understanding how to 
activate potential effector cells against cancerous cells within the immunosuppressive 
 xvii 
tumor microenvironment is critical to harnessing their cytotoxic function in directing 
cancer cell death. To address this challenge, we developed a novel immunomodulatory 
particle platform that leverages the potential of resident CD8+ T cells to better elicit 
tumor-specific cytotoxicity. 
 The particles simultaneously display tumor targeting molecules and anti-CD3 
molecules to activate resident immune cells. To understand the immune activation 
effects, we varied particle size and anti-CD3 antibody density to identify 300 nm particles 
with a surface conjugation density of approximately 41% lead to the greatest amount of 
granzyme B release from Jurkat cells, compared to 3 μm and 1 μm particles. We 
demonstrate that via treatment with this particle, we can elicit higher T cell activation and 
cytotoxicity responses, including proliferation, CD107a expression, and cancer cell death 
in comparison to equivalent amounts of soluble anti-CD3 antibody. Synergizing the anti-
CD3 particles with anti-CD28 antibody conjugation resulted in greater T cell activation 
responses, by increasing the extent of cytoskeletal remodeling, driving increased immune 
synapse formation, cell softening, and longer and more frequent T cell binding to cancer 
cells. We further explore the hypothesis that employing Janus particles to separate the 
anti-CD3/28-T cell activating signal from the cancer cell binding signal (anti-folate 
receptor) could beneficially impact the cancer cell specificity of cytotoxicity. We found 
that delivering these molecules using the Janus particle system, compared to uniformly 
coating particles with all three antibodies, resulted in not only increased cancer cell 
specificity but increased the percentage of targeted cancer cell death. Ovarian tumor 
spheroid models treated with Janus particles resulted in increased cytotoxicity and T cell 
infiltration. Interestingly, when we included a second cancer-targeting molecule, the 
 xviii 
degree of cytotoxicity in the targeted cancer cell line did not increase. However, 
cytotoxicity in the untargeted cancer cell line decreased. These findings represent an 
improved understanding of the cellular processes particle-based immunotherapeutic 
strategies must address in reestablishing anti-cancer effector immune responses within 
the immunosuppressive tumor microenvironment. 
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CHAPTER 1. INTRODUCTION AND SPECIFIC AIMS 
Cancer cells evade and suppress the immune response using a variety of intrinsic and 
extrinsic mechanisms, including downregulating proteins recognized by immune cells 
and expressing or secreting molecules that suppress effector immune cell function(1-3). 
For example, a resident CD8+ T cell may not recognize a tumor cell if MHC expression 
is downregulated on the cancer cell surface. Additionally, an immune response could be 
rendered nonfunctional if the tumor secretes anti-inflammatory cytokines, such as IL-10 
and TGF-β(4, 5). It is well understood that reestablishing a robust immune response 
against cancer cells within the immunosuppressive tumor microenvironment is critically 
important to improve patient outcomes. However, given the propensity of cancer cells to 
mutate, changing their expression of specific cell markers, current immunotherapeutic 
strategies that rely on cancer cells expressing a particular protein may sometimes only be 
temporarily effective(6-8). Therefore, non-antigen specific activation of immune cells 
should be considered as an immunotherapeutic strategy as tumor cells cannot easily 
escape immune recognition. We propose a novel particle platform in which T cells are 
activated in a non-antigen-specific manner but targeted to cancer cells through the 
particle, producing an artificial cancer cell-specific immune response. 
The overall objective of this dissertation is to explore the anti-cancer effects of 
immune-activating Janus particles. Janus particles occupy a unique space within cancer 
immunotherapy – by displaying T cell activating molecules and cancer targeting 
antibodies in a spatially segregated manner, this novel particle platform acts as a hybrid 
of two immunotherapies: T cell engaging bispecific antibodies and artificial antigen 
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presenting cells. The advantages offered by both strategies (i.e. cancer cell-effector 
immune cell ligation following T cell engaging bispecific antibody (T-BsAb) treatment, 
highly concentrated and localized signal on an APC) are included in the design of our 
Janus particles. By targeting cancer cells using antibodies conjugated to one hemisphere 
of the Janus particle whilst simultaneously binding and activating T cells using anti-
CD3/28 antibodies functionalized to the other hemisphere, we can kill cancer cells in a 
targeted manner, thereby increasing the overall amount of T cell cyotoxic response. 
The purpose of this current work is to develop to a particle platform capable of 
activating all bystander T cells against cancer cells regardless of antigen specificity. Non-
specific T cell activation within the tumor microenvironment offers the advantage of 
stimulating all cells present – not only effector T cells that that are specific for a tumor 
associated antigen. Ultimately, the overall objective of this work is to develop a Janus 
particle platform capable of eliciting a non-specific T cell activation response against 
specific cancer cells. The central hypothesis of this project is that concentrated molecular 
signals on particles will lead to sustained T cell activation in both 2D and 3D in vitro 
cancer cell cultures, leading to enhanced cancer cell targeting and cytotoxicity. This 
hypothesis is investigated through the following specific aims: 
1.1 Specific Aim 1: Characterize the effects of anti-CD3 and anti-CD3/28 
functionalized particles on T cell activation and immune synapse formation. 
We hypothesize that anti-CD3/28 presentation affects T cell activation and cytotoxicity 
through variation of particle size, antibody density, and anti-CD3: anti-CD28 antibody 
ratios. We fabricated particles that were delivered to T cells to quantify activation and 
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binding activity using ELISA and flow cytometry, respectively. Cancer cell death was 
measured using standard live/dead flow cytometric assays. The biophysical implications 
of activating T cells with particles were also assessed with AFM, cytoskeleton and 
immune synapse imaging, and a motility assay; we found cells soften upon activation, 
driven by changes in cytoskeleton arrangements. 
1.2 Specific Aim 2: Evaluate the effects of spatially segregating the biological 
signals to crosslink T cells and cancer cells and provoke downstream 
cytotoxicity. 
A novel Janus particle fabrication protocol was established to spatially isolate and 
concentrate signals that stimulate T cells and target ovarian cancer cells. Multi-
functionality was determined using flow cytometry and spatial segregation was 
confirmed using fluorescent microscopy. We hypothesized that Janus particle 
presentation of T cell activating (anti-CD3/28 antibodies) and cancer cell targeting 
molecules (anti-folate receptor (FR) with and without anti-e-cadherin antibody) would 
facilitate T cell cytotoxicity against a cognate cancer cell. Cell crosslinking will be 
measured using fluorescent microscopy and cytotoxicity assessed with flow cytometry. 
We also tested the Janus particle with a three dimensional cell spheroid as a more 
physiologically relevant model of ovarian cancer than tradition 2D cell cultures. Ovarian 
cancer cell cytotoxicity was assessed via fluorescent imaging of tumor spheroids. 
Confocal microscopy was also used to examine T cell infiltration. 
1.3 Innovation and Significance 
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Conventional methods of treatment for cancer involves surgery, radiation, and/or 
chemotherapy, which has thus far exhibited limited success at treating more advanced 
stages of the disease. Cancer is one of the greatest threats to health worldwide, killing 
over 600,000 people in 2017. There exists an unmet clinical need for therapeutics that can 
improve patient outcomes and quality of life. Lack of an effective immune response plays 
a substantial and critical role in cancer progression and eventual patient death. 
Immunotherapies, such as the Janus particle treatment presented here, offer exciting 
possibilities for treatment as immune cells can be present in the tumor microenvironment 
during all cancer stages and even when in remission. We have demonstrated that T cell 
activation with our particles results in immune synapse formation, cell softening, and 
enhanced granzyme b secretion. The functional effects of stimulation of T cells include 
enhanced cancer cell cytotoxicity from stimulated T cells greater penetration of T cells 
into a solid tumor model. The work presented here represents the first time Janus 
particles have been used as a platform to physically crosslink T cells and cancer cells, 
resulting in more frequent and sustained binding, and thus enhanced specific cancer cell 
cytotoxicity. Taken together, we have gained an improved understanding of the necessary 
cell interactions to elicit endogenous anti-tumor immune responses non-specifically. 
Although biological Janus particles offer the ability to perform multiple functions, 
they have only been used thus far to elicit a single action from a cell, such as endocytosis. 
While uniformly coated, multi-functional micro- and nanoparticles are commonly studied 
in the field of bioengineering for applications such as drug delivery, the utilization of 
Janus particles to perform two spatially and temporally linked biological activities, both 
at high potency, is highly innovative and has not yet been investigated as a potential 
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treatment for cancer. The flexible design is capable of multiplexing a variety of signaling 
and bioresponsive behaviors limited only by the signaling molecules incorporated and 
particle biophysical properties. By combining microfabrication and bioengineering 
techniques, we can leverage Janus particles to address known problems in the field of 
ovarian cancer immunoengineering, summarized by the following: 
1) Danger from overstimulation of the immune system, which we address by tuning 
the surface density of the activating ligands so that immune cells are not 
excessively stimulated, causing either activation-induced cell death in T cells or 
systemic toxicity. Additionally, we selectively target the cancer cells such that the 
immune stimulatory agent is highly available only within the tumor 
microenvironment. We emphasize the self-limiting nature of the immune 
stimulation through engagement of the body’s homeostatic and clearance 
mechanisms (e.g. phagocytosis); 
2) Likelihood of off-target effects, while cancer antigens are ideally uniquely or 
highly expressed by cancer cells compared to normal tissues, it is not uncommon 
for healthy cells to express low levels of tumor associated antigens, which can 
cause off-targeting. The high avidity enabled by the particle motif can lead to 
improved binding characteristics. However, although this enhanced binding can 
result in non-specific binding, the modular nature of the particle allows a different 
or additional targeting molecule to be utilized with relative ease; 
3) Intratumor heterogeneity, solid tumors are heterogeneous and not all tumor cells 
will express or overexpress a particular cancer associated surface marker 
uniformly, making complete tumor targeting difficult. Additionally, tumors 
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contain many non-cancerous cells that support and promote tumor growth. The 
nature of the Janus particle platform allows for multiple cancer or cancer-
associated markers to be included for targeting purposes, so that all relevant cells 
may be included in this immunotherapeutic strategy; 
4) Antigen specificity, the Janus particle motif in which targeting and immune-
activating molecules are simultaneously displayed contributes to a degree of 
specificity (present due to the targeting molecules), despite non-antigen specific 
activation. Furthermore, the anti-tumor immune response would not depend on 
immune recognition, which cancer cells can escape via immunoediting; 
5) Difficulty in application to new diseases, which we address through the modular 
nature of the particles, with targeting and cytotoxic mechanisms easily swapped 
with appropriate biomolecules. 
The benefit of spatially segregated bifunctionality, in comparison to mixed 
distributions on single particles, is that a higher density of signaling ligands will increase 
binding and stimulative properties through multivalent interactions(9-11). This 
technology will provide a platform in which particle multifunctionality is possible 
without reducing the intensity of signal. Thus, the Janus particle platform represents a 
substantive depature from current approaches. Our technology is highly novel and should 
prove useful in providing insight into the effects spatial coordination of signaling 
molecules on a single particle and concurrent activation of T cells and cell targeting has 
in eliciting cell-specific death. 
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CHAPTER 2. LITERATURE REVIEW 
2.1 Ovarian Cancer 
Ovarian cancer is the most common gynecological malignancy and the most lethal. Over 
20,000 new patients are diagnosed with ovarian cancer each year in the United States 
resulting in more than 14,000 deaths per year(12, 13). The exact mechanism(s) in which 
cells transform into malignant cells is unresolved, but spontaneous cell mutations induced 
via genetics or environmental factors (including diet and tobacco use) and chronic 
inflammation are thought to contribute (3, 14, 15). 
The most immunogenic cancer cells are continually removed by the immune 
system until a population of tumor cells escape recognition and grow unchecked(7). 
Tumor cell evasion can occur by several different mechanisms, including loss of tumor 
antigen expression, loss of MHC-I expression, or expression of oncogenes. Once 
established, tumors cells will leave the primary tumor and spread either locally to nearby 
healthy tissue or regionally to lymph nodes or other organs and tissues. Ovarian cancer is 
unique in that its development and spread occurs within the peritoneal cavity – a unique 
environment for both tumor growth and immune responses. Ovarian cancer metastasis is 
understood to mostly occur via peritoneal fluid flow that carries sloughed off cancerous 
cells from the primary tumor elsewhere. However, recent studies suggest that ovarian 
cancer metastasis can also occur hematogenously(16). Regardless of mechanism, 
metastasis is normally localized to the greater omentum, a fatty layer of peritoneal tissue 
that wraps around the colon, stomach, and spleen(17, 18). Tumor cells can be shed at a 
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very early stage of the disease, contributing to malignant ascites formation and 
metastasis(15, 19). 
In addition to malignant cancer cells, cancer tissues also include immune cells, 
fibroblasts, endothelial cells, and ECM components(20). These cells contribute to the 
tumor microenvironment and initially exert inhibitory effects on cancer cells; however, 
during tumor progression, tumor cells may circumvent these inhibitory signals or even 
exploit immune and stromal cells for their own growth, invasion, and metastasis(21, 22). 
Cancer associated fibroblasts (CAFs) have been found in omental issues of ovarian 
cancer patients, even without detecting cancer cell infiltration into the omentum(23). 
These cells may arise from local fibroblasts and fibroblasts precursors that differentiate 
based on growth factors and cytokines released by tumor cells(24, 25). Additionally, 
bone marrow cells may be recruited into the tumor niche and differentiate into CAFs or 
they themselves may recruit fibroblasts to adopt the CAF phenotype within the tumor 
milieu(24, 26, 27). Comparative gene expression profiling has revealed that CAFs are 
different from normal fibroblasts and may promote or inhibit cancer growth, depending 
on tumor milieu composition(28). The pro- and anti-tumor effects of these cells will be 
discussed in more detail in the following sections, but overall, the presence of CAFs 
contributes to tumor heterogeneity and therefore may be a possible cell to target using 
immunotherapeutic strategies. 
 Unfortunately, ovarian cancer is often detected only after metastasis, which makes 
it difficult to treat(12). Women diagnosed with stage III and IV ovarian cancer have less 
than a 25% 5-year survival rate because once metastasized, this cancer recurs in 80% of 
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patients(18). If ovarian cancer persists despite repeated chemotherapy treatment, patients 
often develop chemotherapy-resistant strains(29). 
2.2 Host Immune Responses 
The immune system plays at least three distinct roles in preventing cancer: 1) protecting 
the host against viral infection and hence suppresses virus-induced tumors; 2) preventing 
the establishment of an inflammatory environment that facilitates tumorigenesis by 
eliminating pathogens and thus resolving inflammation, and 3) eliminating tumor cells in 
certain tissues because transformed cells often co-express ligands for activation receptors 
on immune cells(7). The immune system response is accomplished by a complex system 
of cells and macromolecules that respond to, kill, and clear diseased and abnormal cells. 
Atypical proteins from cancer cells are processed and presented through multivalent 
forms of the MHC-I/II on APCs (30) and are recognized by CD8+ or CD4+ T cells, 
respectively, through their TCRs, inducing their initial activation. Subsequent activation 
of CD4+ and CD8+ T cells produces startlingly different results between T cell subsets. 
CD8+ T cells – also known as cytotoxic T cells – release cytolytic granules. These 
granules cross the immunological synapse and induce target cells to undergo apoptosis 
within hours of release(31). CD4+ T cells – also known as helper T cells – instead release 
immunosuppressive cytokines, like TNF-α and INF-γ, cytokines that are necessary for the 
differentiation of B cells, activation of macrophages and DCs, and the recruitment of 
inflammatory cells. NK cells are also important for the recognition and cytotoxic 
elimination of tumor cells. 
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Tumor infiltrating lymphocytes (TILs) are especially important in prolonging 
overall survival (OS) in ovarian cancer patients(32-34). In particular, the presence of 
CD8+ T cells is positively correlated with median survival and the ability of CD8+ T 
cells to form memory cells is critical(35). The presence of MHC on ovarian cancer cells 
is associated with not only increased numbers of CD8+ T cells but also increased 
infiltration and proliferation of these lymphocytes(36, 37). 
There is also evidence that the presence of CD20+ B cells correlate with positive patient 
survival in ovarian cancer patients(38). CD20+ B cells have shown to co-localize with 
activated CD8+ T cells, express markers of antigen presentation, and, with CD8+ T cells, 
correlate with increased patient survival(39). Since B cells are not directly responsible for 
tumoricide, it is possible that B cells contribute to a pro-immunogenic immunophenotype 
by secreting cytokines that support CD8+ T cell function and infiltration(40). 
Supporting cells can also play a role in the inhibition or propagation of ovarian cancer. 
TAMs are a major stromal component in solid tumors. In the ovarian tumor 
microenvironment, TAMs are the most abundant subset of infiltrating immune cells(41). 
Classical, M1-polarized, macrophages are activated by INF-γ and characterized by the 
production of pro-inflammatory and immunostimulatory cytokines. M1 macrophages 
express high levels of MHC-1 and II and thus play a critical role in tumor antigen 
presentation. However, M2 macrophages are activated by CD4+ T cell cytokines and thus 
exert anti-inflammatory effects. Recent work shows a correlation between improved 5-
year prognosis and elevated M1:M2 TAMs in patients with ovarian cancer(42).  
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As the omentum is the most common site of ovarian cancer metastasis, we need to 
consider the immune microenvironment of this organ. Like other fatty tissue, the 
omentum is filled with macrophages and a variety of innate or innate-like cells, including 
NK cells(43), NKT cells(44), B cells(45, 46), and DCs(47). These immune cells can be 
induced to act in either a pro- or anti-inflammatory manner, depending on whether the net 
environment is pro- or anti-immunogenic. 
2.3 Immunosuppressive Tumor Microenvironment 
Spontaneous anti-tumor immune responses have only been observed in ~55% of ovarian 
cancer patients, giving rise to the hypothesis that robust immunosuppressive mechanisms 
are employed by these solid tumors(48). In fact, tumor-associated immune responses are 
more likely to facilitate immunosuppression than they are to establish effective antitumor 
responses(3, 21). Broadly, tumors may evade immune system recognition through 
immunoediting and immunoselection or actively suppress antitumor immune responses 
by secreting immunosuppressive signals and recruiting regulatory immune cells. 
Immunosuppressive signals are produced by tumor cells or by other cells located within 
the tumor microenvironment, including stromal and immune cells. New and efficient 
targets for immunotherapeutic that counteract immune system failure could help to 
eradicate tumors and the supporting network of cells that facilitate tumor formation and 
growth. 
An essential tenet of cancer immunosurveillance is that cancer cells express 
antigens different from non-cancerous cells, allowing for specific recognition by immune 
cells. The existence of tumor associated antigens (TAAs) was first demonstrated when 
 12 
researchers found that mice could be immunized against certain tumors and were 
protected upon re-challenge of the same tumor(49). Subsequent studies have revealed that 
such antigens reflect differences in expression levels, mutations, and differentiation 
between cancerous cells and non-transformed cells(7, 50, 51). These TAAs may then be 
recognized by the immune system so that tumor cells can be eliminated through the 
innate and adaptive immune processes. However, tumor cells expressing few or none of 
these TAAs survive to grow and proliferate without immune system recognition(7). 
Additionally tumors can escape recognition by downregulating the expression of MHC-I 
on cancer cell surfaces and/or upregulating the anti-apoptotic molecules FLIP and Bcl-
XL (52-54), driven by a combination of genetic instability and immunoselection(6, 55). 
Additional resistance can occur when tumor cells express mutated, inactive forms of 
death receptors, including DR5 and Fas(56, 57). Such immunoediting results in a tumor 
of poorly immunogenic cell variants that are no longer recognized as dangerous by the 
immune system and can therefore grow progressively(7). This phenomenon is also 
important when considering ovarian cancer recurrence. In one study, ovarian cancer 
patients had their tumor-associated T cells evaluated for recognition of cancer cell 
mutations. In one case, the expression of the mutated gene antigen resulted in an antigen-
specific T cells response; however, the second recurrence showed a loss of T cell 
response despite no change in the expression of the mutated gene, demonstrating immune 
escape between recurrences(8). 
Alternatively, the tumor microenvironment can establish a network of cells and 
proteins that inhibit spontaneous immune processes using a variety of 
immunosuppressive molecules. Tumors often express inhibitory ligands, including PD-
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L1, which inhibit T cell proliferation and effector function and also lead to recruitment of 
Treg cells(58, 59). Research using several cancer systems has shown that cell expression 
of inhibitory immune checkpoint molecules is associated with and contributes to the 
immunosuppressive state of the ovarian cancer tumor microenvironment. Ligation of 
PD1 suppresses the lytic activity of immune effector subsets and its expression on 
monocytes in ascites and blood is correlated with poor clinical outcome(60). The 
expression of the enzyme IDO by tumor cells is associated with advanced stage ovarian 
cancer and impaired patient survival(61). This immunosuppression works to inhibit 
CD8+ T cell proliferation, promote CD4+ T cell apoptosis, and suppress NK cells(62). 
Tumor cells will also secrete anti-inflammatory cytokines, most notably TGF-β and IL-
10, which inhibit the function and infiltration of CD8+ T cells, DCs, and NK cells(5, 52, 
63, 64). Additionally, TGF-β has been implicated in the transformation of effectors T 
cells into Treg cells(65). The TNF network – consisting of TNF-α, IL-6, and CXCL12 – 
is an integrated cytokine network that has been implicated in ovarian tumor 
establishment, growth, and metastasis(14). TNF-α expression is highly correlated with 
increased CXCL12 and IL-6 expression and in one study, ovarian cancer cell exposure to 
TNF-α resulted in proliferation, disrupted cellular organization, and functional loss of the 
basement membrane(66, 67). CXCL12 is found in high levels of malignant ascites and 
significantly, blockade of this chemokine ligand and its receptor, CXCR4, resulted in 
increased patient survival and tumor cell apoptosis, perhaps due decreased recruitment of 
Treg cells(68-70). Tumor cells, infiltrating T cells, and macrophages are the primary 
sources of IL-6. High levels of IL-6 are often detected in ascites and, when found in the 
serum of ovarian cancer patients, are associated with shorter patient survival(71). This is 
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unsurprising, given that IL-6 increases proliferation and angiogenesis and decreases 
sensitivity to apoptotic signals from immune cells, directly contributing to ovarian cancer 
growth and progression(72, 73). Many cancer cells produce VEGF, which is critical for 
establishing a blood supply for the tumor, but also inhibits DC function and NKT cell 
activation(2, 74, 75). It has also been shown that VEGF significantly reduces T cell 
proliferation via VEGFR-2(76). 
Regulatory T cells, myeloid-derived suppressor cells, and tumor associated 
macrophages are the three major immune cell subsets that play key roles in inhibiting 
host immune responses. Treg cells are CD4+ T cells that express CD25 and Foxp3 and, 
when stimulated, inhibit the functions of CD8+ T cells by secreting IL-10 and TGF-β, 
expressing CTLA-4 and PD-L1, and consuming IL-2(77). Treg cells may be recruited to 
the tumor and their presence is associated with reduced patient survival(33, 78, 79). Treg 
cells expressing TNFR2 are a particularly suppressive subpopulation that is found in high 
levels in ascites, thus supporting further cancer growth(80). Specialized Treg cells, 
known as VAT-associated Treg cells, are found in abdominal fat, including the omentum, 
and may accompany cancer cells in malignant ascites. VAT-associated Treg cells support 
cancer cell survival and proliferation and immune evasion by producing cytokines, 
chemokines, and growth factors, such as IL-10, VEGF, and TGF-β(81). Overall, Treg 
cells are critical for tumor progression; experimental tumor models that eliminate Treg 
cells show robust antitumor immune responses(82). Furthermore, accumulation of Treg 
cells in the tumor microenvironment is associated with limited antitumor immunity(83). 
MDSCs are a heterogeneous population of mostly progenitor and immature myeloid cells 
that induce Treg cell differentiation and produce TGF-β. MDSCs have been shown to 
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inhibit T cell activation in ovarian tumors, enhance metastatic and tumorigenic potential, 
and decreased patient survival(84). In the ovarian tumor microenvironment, TAMs are 
the most dominant subset of immune cells(41). In ovarian tumors, M2 macrophages 
contribute to multiple mechanisms of TAM-mediated immunosuppression, mostly by 
upregulating B7-H4 and secreting CCL22. CCL22 produced by tumor cells and TAMs 
direct Tregs to home to the tumor tissue(85). B7-H4 is a member of the B7 family of 
APC regulatory molecules and B7-HA
+
 macrophages significantly decrease T cell 
proliferation and activation(42). TAMs also support ovarian cancer cell adhesion, 
proliferation and metastasis by secreting IL-6, IL-10, CCL18, and TNF-α, among other 
cytokines(14, 65, 86-88). Additional subsets of NKT cells, B cells, and CD8+ T cells 
have shown to exert immunosuppressive effects, although these subtypes are less well 
characterized(89-91). 
Cancer-associated fibroblasts play a significant role in ovarian cancer. Although it 
remains unresolved whether CAFs themselves can induce oncogenic mutations, it is 
evident that CAFs promote tumorigenic activity by supporting cancer cell 
proliferation(92), metastasis(25), and EMT induction(93). Furthermore, CAFs have also 
been shown to facilitate ovarian tumor implantation or metastasis by developing special 
niches within the omentum tissue(25). CAF-derived signals can promote the polarization 
of CD4+ T cells to adoptive a tumor-supportive Th2 phenotype that is associated with 
enhanced infiltration of TAMs and Treg cells(94). Additionally, CAFs secrete IL-6 and 
CCL2 thereby promoting the development of TAMs(95). In general, CAFs contribute to 
the complexity of the tumor microenvironment, suppress immune cell function, and 
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facilitate cancer progression. Addressing the role of these cells is critical in assessing 
immunotherapeutic strategies. 
Collectively, the immunosuppressive mechanisms described are difficult to 
circumvent and facilitate tumor progression by actively restraining endogenous anti-
tumor immunity. As a result of these mechanisms, non-immunogenic tumor cells are 
immunoselected and allowed to grow and proliferate. These tumor and their supporting 
cells then secrete immunosuppression signals that further suppress the immune system 
through a variety of intrinsic and extrinsic mechanisms. As a result of these mechanisms, 
resident effector immune cells, including CD8+ T cells, are unresponsive to cancer cells 
in spite of the presence of signals conventionally triggering activation. 
2.4 Current Immunotherapeutic Approaches 
The FDA has approved immunotherapies for prostate cancer, advanced kidney 
cancer(96), lymphoma, and metastatic melanoma, but have only recently have allowed 
immunotherapies targeting ovarian cancer to enter clinical testing(97). However, studies 
of ovarian cancer patients have implicated immune system suppression is strongly 
associated with negative patient outcomes(12). Thus, ovarian cancer treatment strategies 
should integrate the immune response in order to achieve durable clinical outcomes(98). 
Additionally, as ovarian cancer is largely confined to the abdominal cavity, systemic 
administration of immunotherapeutics may not be necessary; some treatments are already 
delivered into the peritoneum(99, 100). However, overcoming immune suppression is a 
particular challenge in ovarian cancer, as immunosuppressive cells and cytokines have 
been observed in the tumor niche even during remission(101, 102). The two major thrusts 
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of ovarian cancer immunoengineering research are focused on either reversing tumor 
immunosuppression mechanisms or restoring T cell immunological function within the 
tumor environment. To restore immune functionality, researchers are currently 
investigating cancer vaccines that use either proteins or cells to prime T cell responses to 
ovarian cancer antigens(103-106) or adoptive T cell therapy to introduce and increase 
cancer antigen-specific T cells against ovarian cancer cells(107-110). Monoclonal 
antibody therapy is used to both block cancer immunosuppressive strategies and 
reestablish antitumor immunity by targeting cancer cells with blocking agents, anti-TAA 
antibodies, or chemotherapeutic conjugates (111-113). Additionally, pre-clinical studies 
demonstrate that biomaterial immunoengineering approaches offer an exciting alternative 
to better control of molecule presentation and enable tunable immune cell responses with 
increased specificity due to multivalent binding between the targeted cell and the 
biomaterial surface(114, 115). 
2.4.1 Monoclonal Antibody Therapy 
Antibodies, also known as immunoglobulins, are “Y”-shaped proteins composed of a 
consistent Fc stem and a highly variable F(ab)2 portion that recognize antigens. 
Monoclonal antibodies have a high specificity for their antigens and thus can be optimal 
for targeting cancer cells that overexpress certain surface proteins with limited off target 
effects. In the past 20 years, antibody-based therapies for cancers have become a viable 
and well-established therapeutic strategy(98). Antibodies can induce tumor cell apoptosis 
via a variety of mechanisms: complement-dependent cytotoxicity, in which the Fc region 
of the antibody triggers the assembly of the membrane attack complex via the 
complement system to cause cell lysis; antibody-dependent cellular cytotoxicity, a 
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process that involves the Fc region of the antibody binding to Fc receptors on NK cells, 
prompting the release of cytolytic granules to kill cancer cells; immune checkpoint 
inhibition, which works by blocking immunosuppressive molecules, such as CTLA-4 and 
PD-L1; blocking certain metabolism or growth pathways, thereby interfering with the 
ability of cancer cells to grow and survive; and antibody-drug conjugates(116). 
A promising and actively researched strategy includes checkpoint inhibitors 
which are used to bind and block surface molecules on cancer cells and T cells that 
render cytotoxic T cells anergic or apoptotic (101, 117-119). Checkpoint inhibition can 
be achieved using two general strategies: 1) inhibition of immunosuppressive receptors 
expressed by activated T cells, 2) inhibition of ligands of these receptors expressed on 
cancer cell surfaces. CTLA-4, an inhibitory receptor on T cells that prevents T cell 
activation and proliferation but enhances Treg suppression, is being investigated for 
clinical use. Ipilimumab has been used to treat ovarian cancer in a post-vaccine context, 
which elicited modest clinical benefits(120). Although these therapies have shown some 
success, anti-CTLA-4 therapies are associated with more significant immune-related 
toxicities compared with PD-1 blockade(121). PD-1 and PD-L1 blocking antibodies have 
also been studied against a broad range of solid tumors, including ovarian cancer, 
producing variable responses – from no response to complete remission(122-124). PD-1 
antagonists nivolumab and pembrolizumab elicited a disease control rate of 44% and 
34.6%, respectively, in ovarian cancer patients(123, 125). Antagonists to PD-L1 tested in 
ovarian cancer patients include avelumab and BMS-936559; both elicited more 
successful patient outcomes than the non-treatment control group(124, 126). While initial 
results of checkpoint inhibitors in ovarian cancer are promising (~18% progression-free 
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survival after 24 months), they are modest compared to the remarkable results reported 
for melanoma (~27%), renal cell (~53%), non-small cell lung (~32%)(127, 128). 
Solid tumor growth and progression is reliant on neovascularization – the ovarian 
cancer tumor and subsequent formation of ascites depends on the formation of new blood 
vessels to support the abnormally high cellular growth and proliferation present in 
cancer(129, 130). These new blood vessels are rapidly formed and often leaky, due to 
defective basement membranes, and generally tortuous with poor flow(131, 132). The 
endothelial cells within these vessels are more dependent on pro-angiogenic signals than 
more mature vessels found elsewhere in the body. Thus by targeting the receptors for 
these growth factors – such as VEGFR – or targeting the actual protein itself, it is 
possible to disrupt the interaction between growth factor and its receptor, effectively 
limiting tumor growth. Clinicians found that women treated with these antibody therapies 
showed an increase in time of the median progression-free survival (PFS) or recurrence 
of other symptoms but only sometimes increased the median OS(133-139). Tumors also 
may be treated by targeting upregulated proteins involved in metabolism and/or DNA 
repair mechanisms, such as folate receptor, as these proteins are markedly increased in 
cancer cells(140-142). Such antibody therapies have shown to be moderately 
successful(143-145). 
While monoclonal antibody therapy has demonstrated success, particularly 
immune check point therapy, inconsistent outcomes and sometimes only modest benefits 
have been observed. Potential mechanisms underpinning the limited antitumor efficacy of 
monoclonal antibody therapy in ovarian cancer include (1) low intrinsic tumor 
immunogenicity and mutational burden in ovarian cancer compared to other cancers; (2) 
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expression of multiple co-inhibitory receptors on T cells infiltrating ovarian cancer(146); 
(3) compensatory upregulation of multiple immune checkpoints when one is blocked; (4) 
redundant immune suppressive mechanisms. Continued research in this area of 
immunoengineering will hopefully address these concerns by introducing a therapy that 
exhibits multivalency and targeting flexibility. 
2.4.2.1 Bispecific Antibodies 
Another promising approach is bispecific antibodies (i.e. diabodies), which crosslink 
cancer-targeting moieties with T cell-stimulating antibodies using a short peptide linker 
(147-149). For example, Catumaxomab is a trifunctional antibody that specifically targets 
EpCAM on tumor cells and CD3 antigen on T cells and contains an Fc antibody region to 
engage with macrophages, NK cells, and DCs(150). This drug has been approved in 
Europe since 2009 and tested in the United States as a new therapeutic for ovarian cancer 
patients with malignant ascites, increasing PFS and decreasing ascites production(99, 
100, 151). Most significantly, catumaxomab decreased EpCAM+ tumor cells and 
increased CD45+ leukocytes in ascites(100). 
In general, bispecific antibodies (T-BsAbs) have targeted and activated cytotoxic 
T cells using only anti-CD3 antibody (although anti-CD28 antibody is being increasingly 
investigated in tandem with anti-CD3 antibody as well) to circumvent the antigen 
specificity restriction(152). Thus, polyclonal T cells can be stimulated and these 
responses can be directed against cancer cells. However, the design intent behind non-
specific CD8+ T cell activation has had unforeseen consequences – namely the activation 
of other T cell subtypes, including CD4+ T cells, NKT cells, and γδ T cells(153-156). 
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This unintended effect is not entirely unwanted; activation of these effector T cells will 
only enhance immunogenicity. However crosslinking with cancer cells has limited utility 
with these T cell subsets given their inability to directly kill cancer cells (CD4+ T cells) 
or their rarity (NKT cells and γδT cells). Overall, pre-clinical studies of T-BsAbs 
demonstrate robust immunogenic responses – inducing and directing T cells activation 
against tumor cells – and have been tested against over 40 tumor cell antigens, including 
EGFR, EpCAM, HER2, and FR(152, 157, 158). Clinical investigations of anti-CD3 T-
BsAb therapy for numerous cancer types, including acute myeloid leukemia(159) and 
hepatocellular carcinoma(160) are ongoing. However, while more efficacious than other 
antibody therapies(101), the lack of avidity between T-BsAbs and cancer cell or 
immunological synaptic receptors (i.e. TCR, CD3, CD8, and CD28) could limit the 
degree of cytotoxicity of this strategy(98, 101, 116, 161, 162). Nonetheless, the technique 
employed by bispecific antibodies – crosslinking cancer cells with activated T cells 
cancer cell – is clinically significant, effective, and impactful. 
2.4.2 APC Therapy 
By increasing TAA presentation, tumor-specific immune responses are possible – 
including the generation of tumor-antigen specific CD8+ T cells and memory cells. An 
effective APC therapy-induced immune response is superior to any of the other 
commonly used methods of cancer treatment such as chemotherapy, radiation, surgery, or 
even antibody therapy, by inducing an immunologic memory that lingers long after the 
tumor has been cleared away(98). In ovarian cancer patients, MUC-1 treatments have 
shown to be successful, with an increase in in PFS and OS(163). In vivo DC stimulation 
with TAAs has also demonstrated preclinical success using the MSLN-Hsp70 fusion 
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protein – administration to mouse models significantly increased survival, slowed tumor 
progression, and augmented tumor-specific CD8+ T cells responses(164). APC therapy 
also offers the possibility of priming immune responses against multiple tumor antigens, 
thereby reducing the potential for tumor escape(98). This strategy has already shown 
preclinical and clinical success, overall demonstrating an increase in PFS(165). 
2.4.3 Artificial Antigen Presenting Cells 
Studies have shown that cells respond more intensely when presented with highly 
concentrated multivalent signals(166, 167). Thus a particle platform that offers high 
density of activating signal can lead to improved binding and enhanced immune cell 
activation. Freely soluble antibodies, alternatively, do not always provide adequate 
receptor cross-linking to initiate highly active cell responses, especially in cytotoxic T 
cells(115, 168-170). Particle-based T cell activation platforms have been studied to both 
maximize activation responses and better understand the effect particle properties have 
on immune cell activation signaling. Researchers have investigated how particle 
shape(115, 171), molecular density(167, 172), spatial distribution(173), antibody 
orientation(174), and activating molecule(s)(175), and dosing regimens of commercial 
beads and soluble antibody affect immune cell responses. Likely, different particle 
properties are synergistic and few studies isolate particle design parameters or investigate 
the mechanisms behind increased or decreased T cell responses. Because antibodies are 
immobilized, particles provide better control over the spatial presentation of activating 
and targeting antibodies enabling tunable responses for maximal immunotherapeutic 
effect, compared to soluble protein therapies. 
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Artificial APCs are a particular kind of particle-based immunomodulatory 
biomaterial that occupies a unique space between adoptive cell therapy and monoclonal 
antibody therapy in the sense that often, these particles display monoclonal antibodies on 
their surface in order to mimic APC function(161). As endogenous APC activity can be 
tempered by the immunosuppressive tumor microenvironment or by inconsistent/ 
unrecognized cancer antigens (factors which most likely contributed to inconsistent 
clinical trial outcomes), aAPCs are an alternative approach that cannot be influenced by 
immunosuppressive signals and allow for controlled signal presentation of T cell 
activating proteins, traditionally, either anti-CD3 antibody or antigen peptide-MHC 
complex and anti-CD28 antibody(115). 
 In general, aAPC research has been conducted in vitro using a variety of 
platforms, including carbon nanotubes(176), liposomes(177), polystyrene spheres(178), 
and ellipsoid PLGA microparticles(179). All these platforms have demonstrated success 
in eliciting T cell activation in vitro and in vivo against cancer cells(161). Thus far, no in 
vivo toxicities have been observed; however, the typical aAPC – large, rigid, and usually 
non-biodegradable – has led to fears about possible embolisms, making FDA approval of 
these particles difficult(180). Newer studies have focused on nano-size aAPC to promote 
trafficking and reduce possible side effects(162, 173, 175). 
2.4.4.1 Janus Particles 
As Janus particles are multifunctional yet maintain dense molecular presentation through 
spatially segregation, there is potential for how these particles to be used as therapeutic 
agents. However, while Janus particles have been investigated for stimulation of T 
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cells(173, 181, 182) and uptake by macrophages(183, 184) or cancer cells(185), 
researchers have focused on interrogating the effects asymmetry has on cellular response, 
not on prompting a cellular response for a specific downstream outcome. Different T cell 
activation was observed as a result of different molecular patterning with more intense 
and sustained activation triggered by particles with an increased surface coverage of anti-
CD3 antibody(181). However, T cell activation responses displayed higher variability 
than expected, leading the study authors to postulate that cellular response heavily 
depended on particle orientation. A follow-up study(182) in which particle orientation 
was controlled by coating one hemisphere with aluminum and the other with anti-CD3 
antibody revealed distinct differences in T cell activation response. Once the anti-CD3 
antibody functionalized region of the particle was oriented to interact with the T cell, a 
rapid transformation to an activated phenotype was observed. Lee and Yu further 
determined that T cell activation is most effective when stimulated with densely packed 
anti-CD3 antibody and is further enhanced with the presence of anti-CD28 
antibody(173). Gao and Yu also investigated how Janus anti-CD3 antibody/silica 
particles are endocytosed by T cells(186). They found that the asymmetrical nature of 
Janus particles heavily influences cell membrane dynamics and reduced overall particle 
internalization, for all sizes investigated, in comparison to uniformly functionalized 
particles. Taken together, this research establishes the ability of Janus particles to activate 
T cells and prevent internalization, supporting the rationale that the Janus particle 
platform is uniquely suited for cancer immunoengineering purposes. 
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CHAPTER 3. CHARACTERIZE THE EFFECTS OF ANTI-CD3 AND 
ANTI-CD3/28 ON T CELL ACTIVATION 
3.1 Introduction 
The stimulation of cytotoxic T cells is a powerful pre-clinical and clinical technique(159, 
160, 169, 173, 175, 177, 187-190) to directly kill cancer cells. Since cytotoxic t cells are a 
major immune cell type present in certain tumor microenvironments(187, 191), proper 
immunoengineering of their response lessens the need to recruit additional immune cell 
types to the tumor. Classically, cytotoxic T cells are activated in a series of discrete 
signals(115, 189, 192) by TCR signaling initially(177, 193) and then additionally through 
the co-stimulatory molecule CD28 and various cytokines. While these additional 
signaling molecules are required for phenotype stabilization(188, 192), it is possible to 
activate T cells using only anti-CD3 monoclonal antibody to induce T cell activation, 
which includes T cell proliferation, IFN-γ and TNF-α production, cytolytic degranulation, 
and surface expression of activation markers(115, 169, 187, 188, 193). The utility of 
activating effector T cells using anti-CD3 antibody is demonstrated through numerous 
successful clinical investigations of anti-CD3 bispecific antibody therapy for cancers, 
including acute myeloid leukemia(159) and hepatocellular carcinoma(160).  
Cells respond more intensely when presented with highly concentrated 
multivalent signals(114, 166, 167). Thus a particle platform that presents dense activating 
signals can lead to sustained cell binding and enhanced activation. T cell death can also 
occur following this activation, if stimulating antibodies are presented overly 
concentrated or if co-stimulatory molecules are missing. Freely soluble antibodies, 
 26 
alternatively, do not always provide adequate receptor cross-linking to initiate highly 
active cytotoxic T cell response due to monovalent binding behavior(115, 168-170). 
Furthermore, although not investigated in this study, immobilizing anti-CD3 antibody 
results in a more consistent effector phenotype(187), prolonged T cell stimulation, and 
amplified cytokine secretion upon stimulation, compared to soluble anti-CD3 
antibody(168). 
Particle-based T cell activation platforms have been studied to both maximize 
activation responses and better understand the effect particle properties have on immune 
cell activation signaling. Researchers have investigated how particle shape(115, 171), 
molecular density(167, 172), spatial distribution(173), antibody orientation(174), 
activating molecule(s)(175), and dosing regimens of commercial beads or soluble 
antibody affect immune cell responses. However, a lack of complete understanding about 
how to optimize these variables for ideal signal presentation for maximum T cell 
activation and cytotoxicity remains. Likely, different particle properties are synergistic 
but few studies isolate particle design parameters or investigate the mechanisms behind 
altered T cell responses. We and others have established that cellular responses depend 
on how their molecular signals are presented (16, 17, 22). Understanding how activating 
signal presentation affects T cell behavior, from initial activation to downstream 
cytotoxicity, is of critical importance to develop potent biomaterials for 
immunomodulation. Considering the particle and molecular properties that promote T 
cell activation, we investigated the effect of particle size and surface coverage of anti-
CD3 and anti-CD3/28 antibodies on T cell activation responses, including GrB release, 
downstream T cell binding, cancer cell cytotoxicity. 
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Relevant commercial comparisons, including equivalent amounts of soluble anti-
CD3 antibody and commercial activating beads (anti-CD3/28 Dynabeads), were made. 
We evaluated T cell cytotoxicity against cancer cells and determined effector cell-target 
cell interactions were vital for more effective cancer cell death. Furthermore, particle-
elicited cytotoxic death was highly depended on a localized release of cytolytic granules. 
Designing particles for T cell activation and cytotoxicity has far reaching consequences 
to in vitro expansion of certain T cell populations and the modulation of the immune 
response within the tumor microenvironment for immunotherapeutic purposes. 
3.2 Materials and Methods 
3.2.1 Cell Culture 
T cells – Jurkat (ATCC; Manassas, VA), a human cancer T cell line, and primary human 
T cells were cultured in RPMI 1640 cell culture media (ATCC, Manassas, VA) 
supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals; Norcross, GA) 
and 1% penicillin-streptomycin (Sigma Aldrich, St. Louis, MO) and maintained between 
1 x 10
5
 and 1 x 10
6
 cells/mL. Primary human T cells were isolated from peripheral 
human blood using EasySep T cell Isolation Kit (Stem Cell Technologies; Vancouver, 
Canada). The human ovarian cancer cell line HeyA8 was gifted from the McDonald 
laboratory (Georgia Institute of Technology, Atlanta, GA). HeyA8 monolayers were 
cultured using the same cell growth medium as the T cells. All cells were maintained at 
37 °C with 5% CO2. All cells used were below passage 30 with viability assessed using 
trypan blue. 
3.2.2 Particle Functionalization and Characterization 
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Carboxylated polystyrene particles with 0.3 μm, 1.0 μm, and 3.0 μm diameters were 
purchased from Bangs Laboratories (Fishers, IN). Mouse anti-human CD3 antibody alone 
or with mouse anti-human CD28 antibody (Biolegend; San Diego, CA) was conjugated 
to particles using standard 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) 
crosslinking via a PolyLink Protein Coupling Kit for COOH Microspheres (Bangs 
Laboratories, Fishers, IN). Briefly, particles were washed through centrifugation and 
buffer exchange and incubated with 200 mg/mL EDC for 15 minutes at room temperature 
to activate surface carboxylic acid functional groups and then incubated with anti-CD3 
antibody at room temperature for 1 hour on an end-over-end spinner. Particles were 
washed twice to remove unbound linker and unconjugated antibody. A schematic 
illustrating the particle functionalization process is shown in Figure 1. Antibody was 
conjugated to particles at different amounts (0 μg, 6.25 μg, 12.5 μg, 25 μg, 50 μg, and 
100 μg) (Figure 1, Table 1), such that antibody labeling density was kept consistent on 
different particle sizes by normalizing the conjugation reaction to total surface area. 0.3 
μm particles conjugated with 25 μg bovine serum albumin (BSA; Sigma Aldrich) were 
also created using this method. Anti-CD3/28 particles were conjugated using EDC at the 
following conditions: 25μg anti-CD3 with 6.25 μg, 12.5 μg, 25 μg, 50 μg and 100 μg 
anti-CD28 antibody. 
Table 1: Surface Saturation. 










Figure 1: Particle Conjugation Schematic. Schematic of anti-CD3 antibody 
functionalization of three sizes of carboxylated polystyrene particles at varying labeling 
densities using EDC. 
 Batch conjugation uniformity was investigated using dynamic light scattering 
(DLS). A 90 Plus Particle Size Analyzer (Brookhaven Instruments Corporation, 
Holtsville, NY) was used to measure the dispersity index of each particle condition. The 
particle population was analyzed by averaging ten particle measurements taken during 
each run. To evaluate varying antibody conjugation to the particles, the post-conjugation 
supernatant was evaluated for protein content at 280nm wavelength using a BioTek 
Synergy H4 Hybrid plate reader (Biotek Instruments, Winooski, VT), which was 
quantified from standard curve measurements. FITC goat anti-mouse IgG, Fcγ fragment 
specific and Alexa Fluor® 647 goat anti-mouse IgG, F(ab’)2 fragment specific (Jackson 
ImmunoResearch Laboratories, West Grove PA) were used to label the respective Fc and 
F(ab)2 portions of the primary anti-CD3 antibody. Briefly, each antibody was diluted in 
blocking solution (phosphate buffered saline (PBS; Invitrogen, Grand Island, NY) 
containing 0.02% FBS and incubated with the anti-CD3 antibody functionalized particles 
on ice in the dark for 1 hour. Each sample was washed and resuspended in PBS. The 
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fluorescent F(ab’)2 fragment specific secondary antibody was incubated at 1:200 and the 
fluorescent Fcγ fragment specific secondary antibody was incubated and 1:50. The MFI 
of these fluorescently tagged particles was measured using flow cytometry. Surface 
saturation values were calculated at each particle size and conjugation density, using the 
following equation provided by Bangs Laboratories, 
 
   
 
    
   
 
(1) 
in which S is the amount of protein on the particle surface, ρS is the density of the particle 
sphere, d is the particle diameter, and C is the capacity of the particle surface for the 
protein of interest. For human IgG, we assumed C ≈ 2.5 mg/m
2
. 
3.2.3 T Cell Activation 
A granzyme B ELISA assay (Biolegend, San Diego, CA) was used to evaluate the 
magnitude of T cell activation as a result of treating Jurkat cells with our anti-CD3 
particles in vitro. This kit measures the concentration of GrB secreted into the cell media 
following T cell stimulation thereby measuring the extent of T cell activation. Jurkat cells 
were seeded at 0.2 x 10
6
 cells/mL in a 96 well plate (Corning) and treated with 
approximately 2 x 10
6
 particles; each size and antibody labeling density was tested. 
Following 24 hours of cell incubation with the particles, the contents of the well were 
collected and the stimulated T cell supernatant was isolated by centrifugation. GrB 
secretion was measured in the supernatant using sandwich ELISA according to the 
manufacturer’s specifications. When we examined particle size only, an equivalent 
amount of antibody was delivered between conditions (equal to 3.0 μm particles), as 
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opposed to number of particles. Our selected particle was compared to reagents currently 
in use – commercially available T cell activation particles, Dynabeads® labeled with 
anti-CD3 and -CD28 antibodies (Life Technologies; Grand Island, NY), and soluble anti-
CD3 antibody. Unlabeled particles were used as negative controls. Dynabeads were 
delivered per the manufacturer’s protocol. To perform time-course studies, separate wells 
were utilized. Once the cell supernatant was harvested, it was flash-frozen in liquid 
nitrogen and stored at -80 °C until all samples were collected. Frozen cell supernatant 
was thawed in a 37 °C water bath before analysis with ELISA. 
Primary human T cell proliferation was also measured as a marker of T cell 
activation using Vybrant® CFDA SE (CFSE, Thermo Fisher Scientific, Waltham, MA) 
and stimulated with the optimized anti-CD3 particle, anti-CD3/28 particle formulations, 
or BSA-labeled particle. Primary human T cells were plated at 1 x 10
6
 cells/mL in a 12 
well tissue culture plate, stained according to the manufacturer’s specifications, and 
monitored with the particle treatments for 10 days. On days 4 and 7, 150 μL from each 
sample was collected, washed, resuspended in PBS and analyzed using flow cytometry. 
On day 10, the fluorescent intensity of all remaining cells was measured. Cells were 
cultured as usual for the duration of the assay, in the dark. 
3.2.4 T cell Cytotoxicity 
The ability of our anti-CD3 and anti-CD3/28 particles to induce cancer cell death was 
evaluated using a direct co-culture. HEYA8 cells, an ovarian cancer cell line, were plated 
at 0.1 x 10
6
 cells/mL in 12-well cell culture plates and allowed to reach homeostasis. 
After 24 hours, Jurkat cells were added at an identical concentration and dosed with 0.3 
μm particles (~20 x 10
12
 particles/μL) functionalized with anti-CD3 or anti-CD3/28 
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antibody. Following 24 hour incubation, the contents of the entire well were collected to 
analyze viability using a live/dead stain (Invitrogen; Eugene, OR). Calcein AM identified 
viable cells and ethidium homodimer-1 (EthD-1) stained dead cells. Flow cytometry was 
used to identify non-viable cancer cells. At least 25,000 events were recorded for each 
sample. To generate a positive control of dead cells, both HEYA8 and Jurkat cells were 
incubated in a 60⁰C water bath for 30 minutes. When considering our anti-CD3/28 
particles, primary human T cells were used to evaluate cytotoxicity. T cell viability 
following particle treatment was assessed by staining T cells for with APC anti-human 
CD3 (Biolegend). 
Additional cytotoxicity experiments were carried out with conditioned media and 
with transwell assays. Conditioned media was generated by seeding 0.1 x 10
6
 cells/mL in 
12-well cell culture plates and then dosing with our optimized particle for 24 hours. The 
activated Jurkat-conditioned media was harvested and used to treat an equivalent number 
HEYA8 cells for 24 hours. Transwell experiments were performed by seeding 0.1 x 10
6
 
HeyA8 cells/mL in 12-well cell culture plates and an equivalent number of Jurkat cells in 
the transwell. The transwell compartment further contained the optimized particle. 
Cancer cell cytotoxicity was assessed using the method described above. 
HeyA8 cells grown on coverslips and dosed with our particle treatments were 
imaged using fluorescent microscopy. Cells remaining on the coverslip were stained with 
the live/dead staining cocktail and imaged at 20x magnification using fluorescence 
microscopy. 20 images per sample were taken. 
Cytotoxicity was also measured by fluorescently staining for the presence of 
CD107a, a marker of degranulation. Briefly, primary human T cells were dosed with the 
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relevant treatment groups, incubated for 24 hours, and then assessed for FITC mouse 
anti-human CD107a (Biolegend) using flow cytometry. 
3.2.5 Cytotoxic Co-Culture Interactions 
The effect of our particle treatment on T cell and cancer cell interactions was assessed by 
time-lapse live cell imaging. We plated 1.0 x 10
4
 cells/mL HeyA8 cells into 24 well 
culture plates, allowed them to adhere for 24 hours, and then seeded an equivalent 
number of Jurkat cells and dosed with our anti-CD3 particles, soluble anti-CD3, anti-
CD3/28 Dynabeads, BSA particles, or left untreated. Co-cultures were allowed to 
incubate for one hour and then the plate was transferred to the BioTek Cytation 3 
Imaging plate reader (BioTek Instruments). Bright field images of each well were taken 
at 10x magnification every three minutes for four hours using the Gen5 software (BioTek 
Instruments). The plate was shaken after each cycle of imaging to displace non-bound T 
cells. During this time, cells were maintained at 37 ⁰C and 5% CO2. Binding events and 
duration was quantified by observing differences between frames. A cell was evaluated 
as bound if the Jurkat cell moved less than 5 μm and the interaction lasted for two or 
more frames. 
3.2.6 Statistical Analysis 
Statistical analysis was conducted in Graphpad Prism (La Jolla, CA) using one way or 
two-way ANOVA to determine significance of variables. Post-hoc Tukey-Kramer HSD 




3.3.1 Anti-CD3 Particle Functionalization 
Anti-CD3 antibody was conjugated onto 0.3 μm, 1.0 μm, and 3.0 μm carboxylated 
polystyrene particles, as depicted in Figure 1 and described in the methods section, such 
that all particle sizes displayed equivalent surface saturations at six different labeling 
densities (Table 1). As shown in Figure 2A, increasing the amount of soluble anti-CD3 
antibody in the conjugation reaction resulted in increased protein conjugated to the 
particle surfaces. The dispersity index of the particles, a measure of particle size 
uniformity, was assessed by dynamic light scattering (DLS) and all particles exhibited 
size uniformity post-conjugation (Figure 2B).  
 
Figure 2: Particle Characterization. (A) Antibody content on particles was calculated 
by measuring the absorbance of particle supernatants post-conjugation at 280 nm. Data 
are represented as mean ± SEM, n=4. (B) Anti-CD3 particles were analyzed using DLS 
to calculate the size heterogeneity of the particle population, n=10. 
3.3.2 Anti-CD3 Particles Triggers Granzyme B Secretion 
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Following conjugation, the effect of anti-CD3 surface density on T cell activation was 
characterized. We incubated T cells with equal moles anti-CD3 particles at all 
conjugation densities and found that, in general, delivering particles with increased anti-
CD3 surface density resulted in increased GrB release, indicating a higher degree of T 
cell activation (Figure 3). Between the 0 μg anti-CD3 control and the best-performing 
anti-CD3 surface coverage, we observed nearly a three-fold increase in GrB release for 
3.0 (p<0.05) and 1.0 μm particles, and a two-fold increase for 0.3 μm particles. However, 
in all three particle sizes, the particle condition with the highest amount of anti-CD3 
antibody did not elicit the greatest amount of GrB secretion. We investigated this 
observation by characterizing the F(ab)2 region accessibility (the antibody region 
associated with TCR binding and subsequent T cell activation) using a region-specific 
fluorescent antibody. As shown in Figure 3A, the fluorescent intensity of both region-
specific markers increase as the antibody labeling density also increases, until the highest 
or second-highest conjugation density – 100 μg or 50 μg. This matches the trend 
observed in the GrB release data. At these high densities, F(ab)2 region availability is 
reduced; Fc region availability, however, continues to increase at these high 
functionalization amounts. We determined GrB secretion is positively correlated with 
F(ab) regions accessibility (Table 2); greater F(ab)2 region availability should elicit 
increased T cell binding and thus, greater T cell activation. Fc region accessibility is less 
correlated than the F(ab)2 region. At each particle size investigated, the antibody 
conjugation density resulting in peak GrB release, similarly resulted in maximal F(ab)2 
region availability (Figure 3A). This result indicates that T cell activation is dependent 
on anti-CD3 F(ab)2 region accessibility. 
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Table 2: Pearson's Correlation Coefficient. 
Particle Size (μm) F(ab)2 Fc 
3.0 0.965 0.006 
1.0 0.82 0.563 
0.3 0.827 0.751 
 
 
Figure 3: Particle Size and Conjugation Density Effect on Granzyme B Secretion. 
(A, B) Quantification of granzyme B secretion of 3.0 μm, 1.0 μm, and 0.3 μm particle 
sizes (A) and at 25 μg anti-CD3 antibody (B). Cells and particles were incubated together 
for 24 hours before isolating the supernatant and performing ELISA analysis. Data are 
represented as mean ± SEM, n=6(a), n=5; *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 (B). Anti-CD3 particles labeled with F(ab)2-specific () or Fc-specific 
() fluorescent secondary antibodies were measured for intensity using flow cytometry. 
n=3. 
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In order to de-couple the amount of anti-CD3 antibody delivered via particle from 
the particle size (as larger particles will present more T cell-activating antibodies than 
smaller particles, resulting in greater GrB secretion as shown in Figure 3A), we treated T 
cells with an equivalent amount of antibody using 25 μg conjugation densities at all 
particle sizes. Particle surface area was scaled so that we delivered the same dose 
originally administered with 3.0 μm particles. When equal amounts of total antibody 
were delivered, the 0.3 μm particles induced significantly greater GrB secretion than its 0 
μg negative control (p<0.0001) and also the 3.0 μm and 1.0 μm particle sizes (Figure 3B, 
***p<0.001 and **p<0.01, respectively), signifying that particle-elicited T cell activation 
is size-dependent. The fact that 0.3 μm particles did not elicit significantly greater GrB 
secretion than its 0 μg negative control until the anti-CD3 antibody dose increased 
(p<0.0001) also demonstrates the dose-sensitivity of T cell activation. 
3.3.3 Anti-CD3 Antibody Immobilized on Particles Increase T cell Activation 
Based on the above results, 0.3 μm particles emerged as the best performing particles to 
maximize T cell GrB secretion. The 25 μg condition (approximately 41% surface 
coverage, as calculated in Table 1) was further selected for continued investigation as the 
highest anti-CD3 F(ab)-region accessibility was observed for this conjugation density. 
We hypothesized that anti-CD3 particles would initiate stronger T cell activation 
responses than soluble antibody due to the multivalent activation signal presented by our 
particles. Further comparison of commercially available anti-CD3/28 Dynabeads was 
investigated. The proliferative effect of anti-CD3 particles on T cells was determined by 
measuring the depletion of CSFE – a tracer molecule that covalently binds inside cells 
and decreases in fluorescent intensity with each subsequent cell division. After incubating 
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primary human T cells with particles for five days, treatment with anti-CD3 particles 
results in significantly higher proliferation than untreated, BSA particle-, and soluble 
anti-CD3 antibody- treated T cells, as represented in Figure 4A. The higher proliferation 
is reflected by the significantly lower percentage of first generation cells (*p<0.05, 
***p<0.001) and greater percentage of third generation cells (#p<0.001, ****p<0.0001). 
Anti-CD3/28 Dynabeads elicited similar proliferative responses to anti-CD3 particles 
with no significant differences. 
 
Figure 4: T cell Activation Responses by Particles. (A) Human primary T cell 
proliferation following incubation with anti-CD3 particles, commercial antibody 
activators, or negative controls for 5 days. Data are mean ± SEM, n=3; *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001,  = p<0.001 to anti-CD3/28 Dynabeads, # = 
p<0.001 to anti-CD3 particles. (B) anti-CD3 particle-elicited granzyme b secretion was 
compared to soluble antibody and commercially standard activation particles, n=3. 
We then investigated the ability of our anti-CD3 particles to trigger GrB release 
compared to soluble antibody and commercial anti-CD3/28 Dynabeads. Activation from 
the anti-CD3 particles were determined by quantifying the concentration of GrB secreted 
using an ELISA immunoassay, and unconjugated particles and untreated cells were used 
as negative controls (Figure 4B). The results indicate that anti-CD3 particles and 
commercial anti-CD3/28 beads caused significant T cell activation (p<0.01); in contrast, 
an equivalent dose of soluble anti-CD3 antibody elicited substantially reduced GrB 
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release. These results indicate that immobilization of activating molecules enhances their 
effect, likely due to multivalent interactions between the particles and cells. 
3.3.4 Anti-CD3 Functionalized Particles Provoke Significant T cell Cytotoxicity to 
Cancer Cells 
Cytotoxic death of cancer cells via cytolytic granule release relies on the strength of the T 
cell activation response, so ensuring particle-elicited cytolytic granule secretion from T 
cells was deadly to cancer cells was critical. Cancer cells and Jurkat cells were incubated 
together and cancer cell death assessed after treatment. The results in Figure 5A show 
that anti-CD3 particles caused a doubling of percentage of cancer cell death (p<0.0001) – 
approximately 60% cytotoxicity—as opposed to less than 30% observed following 
treatment with negative controls. Lower levels of T cell mediated cancer cell cytotoxicity 
was also observed for the commercial anti-CD3/28 particles and the equivalent dosage of 
soluble anti-CD3 antibody, compared to anti-CD3 particles. Images of cancer cells 
exposed to T cells and treatments are shown in Figure 5B. We observed extensive 
detachment, altered morphology, and dramatically fewer alive-stained cells compared to 
soluble antibody and negative controls, which strongly indicates that anti-CD3 particles 
can elicit a powerful cytotoxic effect against cells. We calculated the correlation between 
cancer cell cytotoxicity and the previously quantified GrB secretion data and found these 
two data sets displayed a positive correlation, demonstrating an association between the 
extent of T cell activation and the degree of cytotoxicity (Figure 6). 
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Figure 5: T Cell Cytotoxicity. (A) Co-cultures were treated with T cells and various 
treatments. Cancer cell death from T cell cytotoxicity was assessed by measuring 
live/dead fluorescent stain with flow cytometry. n=6. (B) Cancer cells were seeded onto 
coverslips before co-incubation with particles and T cells. Following 24 hours, cells were 
fluorescently labelled with live/dead stain. Representative images of each condition are 
shown. n=4, scale bar = 200 μm. (C) CD107a expression was quantified in human 
primary T cells isolated from peripheral blood using flow cytometry to measure 




Figure 6: Correlation between Granzyme B Secretion and Cytotoxicity. Values of 
cytotoxicity (%) and Granzyme B (pg/mL) were plotted against each other for each 
condition tested for 3.0 μm particles. 
 We measured the expression of CD107a using primary human T cells. Soluble 
anti-CD3 antibody did not elicit a greater percentage of cell degranulation than our 
negative controls (Untreated and BSA particles) but were significantly less than anti-
CD3/28 Dynabeads (p<0.0001) and our anti-CD3 particles (p<0.01). Our anti-CD3 
particles and commercially available Dynabead treatment also resulted in significantly 
greater degranulation than negative controls; however, the percentage of cell 
degranulation was higher post-treatment with Dynabeads in comparison to our anti-CD3 
particles (p<0.01). This result suggests that that although our anti-CD3 particles are 
eliciting fewer cytotoxic responses from T cells compared to anti-CD3/28 Dynabeads 
(Figure 5C), the resulting cytotoxicity is greater in intensity, causing higher cancer cell 
death (Figure 5A-B). 
 While the effectiveness of this treatment is evident, there is no specificity in 
regards to the cells killed by anti-CD3 particles, as shown in Figure 7. Anti-CD3 particles 
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elicited significantly higher cytotoxicity than no particles or the BSA particle control for 
all cell lines tested, including the “healthy” hDF cell line (p<0.001). These results suggest 
that the T cell activation response generated by our anti-CD3 particles is sufficiently 
robust and may be used ubiquitously to treat any cancer. However, these data also 
indicate that off target effects would be a major limitation of this approach. 
 
Figure 7: Anti-CD3 Particle elicits Non-Specific Cell Death. Three different cells 
lines, two ovarian cancer (HeyA8 and Ovcar-3) and one immortalized cell line from 
healthy dermal fibroblasts were dosed with anti-CD3 particles using identical conditions. 
Data are represented as mean ± SEM; n=6; ****p<0.0001. 
 Increased cytotoxicity is not exclusive to cancer cells. When we evaluated 
T cell viability following particle activation and incubation with cancer cells, T cells were 
significantly less viable after anti-CD3 particle stimulation, compared to Dynabeads, 
soluble anti-CD3 antibody, and negative controls (p<0.0001). Dynabeads elicited a slight 
decrease in viability compared to untreated T cell co-cultures (p<0.05). The increase in T 
cell death following activation, particularly after treatment with anti-CD3 particles, is 
likely two-fold: 1) activation-induced cell death due to repeated stimulation, and 2) the 
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release of cytolytic granules that caused cancer cell death (Error! Reference source not 
ound.), also lead to T cell death. The magnitude of T cell death following anti-CD3 
particle treatment is undeniably tied to the stronger activation responses we observed in 
Figure 1F, in comparison to Dynabeads. 
 
Figure 8: Jurkat cell viability. Co-cultures were treated with T cells and various 
treatments. T cell death from cytolytic granule release was assessed by measuring 
live/dead fluorescent stain with flow cytometry. Data are represented as mean ± SEM, 
*p<0.05, ****p<0.0001, n=6. 
3.3.5 Unencumbered Interaction of T cells with Cancer Cells is Critical for Cytotoxicity 
As T cells typically kill cancer cells by directly engaging via TCR—MHC-I interactions, 
we examined both the necessity of T cell and cancer cell interactions and whether our 
anti-CD3 particles promote them. The extent to which we restrict T cell-cancer cell 
interactions, and its effect on cytotoxicity, was investigated using three different 
cytotoxic experimental designs: conditioned media, transwell, and direct co-culture as 
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described in Figure 9. This result shows that direct co-culture elicited higher levels of 
cytotoxicity than both the conditioned media (p<0.001) and transwell (p<0.01) 
conditions, demonstrating that the ability of Jurkat cells to freely interact and come into 
close proximity with cancer cells is critical for significant cytotoxicity. Additionally, a 
delayed exposure to cytolytic granules reduced cancer cell death, although not 
significantly, as shown in Figure 10. This is unsurprising; the T cell cytotoxic milieu is 
dynamic, with unsteady secretion of activation products (Figure 10). 
 
Figure 9: Experimental Design effects on Cytotoxicity. Three experimental design 
conditions–conditioned media, transwell, and direct co-culture–were assessed for 
effective cytotoxicity. Schematics of the set-ups are depicted above the graph. Data are 
represented as mean ± SEM, n=5; **p<0.01, ***p<0.001. 
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Figure 10: Granzyme B Secretion varies over 24 hours. Jurkat cells were activated 
using anti-CD3 particles and, over the course of 24 hours, conditioned cell media samples 
were taken, flash frozen, and then measured for GrB content at the end of the experiment. 
Data are represented as mean ± SEM, n=5; data not significant. 
3.3.6 Inclusion of anti-CD28 onto anti-CD3 Functionalized Particles Amplifies T cell 
Activation 
We tested the effect of adding co-stimulation by functionalizing particles with anti-CD3 
and anti-CD28 antibody on T cell activation. We investigated five different particle 
conditions: 1:4 anti-CD3/28, 1:2 anti-CD3/28, 1:1 anti-CD3/28, 2:1 anti-CD3/28 and 4:1 
anti-CD3/28 antibodies, and assessed the effect on cell targeting and proliferation on 
primary human T cells. Figure 11A shows that 1:2 anti-CD3/28 particles bound to 
significantly fewer particles than any other condition (p<0.01 at least). Additionally, 
following five day incubation with all particle conditions, 1:2 anti-CD3/28 (p<0.01) and 
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1:4 anti-CD3/28 particles (p<0.05) elicited higher proliferation than 1:1 anti-CD3/28 
particles (Figure 11B). 
 
Figure 11: Effect of anti-CD3: anti-CD28 Antibody Ratios on T cell Binding and 
Proliferation. (A) Primary human T cells were incubated with various formulations of 
CD3/28 particles and the percentage of cells with particles bound was measured using 
flow cytometry. Data are mean ± SEM, n=3; **p<0.01, ***p<0.001, ****p<0.0001. (B) 
T cells were stained with CFSE and incubated with functionalized particles for five days 
before analyzing using flow cytometer. n=4; *p<0.05. 
 Based on our findings presented in Figure 4, we hypothesized that increased 
proliferation response was a result of increased particle interactions with T cells. As 
shown in Figure 12A, incubating primary human T cells with our particles (anti-CD3, 
anti-CD28, and 1:4 anti-CD3/28) led to significantly increased binding compared to anti-
CD3/28 Dynabeads (p<0.0001) or our negative controls (p<0.0001). The effect of these 
interactions was further examined by measuring cell proliferation following five day 
incubation (Figure 12B). 1:4 anti-CD3/28 particles elicited greater proliferation than anti-
CD3/28 Dynabeads (p<0.01) and anti-CD3 particles (p<0.001). Unexpectedly, there were 
no differences between anti-CD28 particles and 1:4 anti-CD3/28 particles. 
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Figure 12: T cell Activation from anti-CD3/28 Particles. (A) T cells were incubated 
with anti-CD3, anti-CD28, 1:4 anti-CD3/28 particles and anti-CD3/28 Dynabeads and 
measured for the percentage of cells with particles bound using flow cytometry. Data are 
mean ± SEM, n=3; ****p<0.0001. (B) T cells were stained with CFSE and incubated 
with functionalized particles for five days before analyzing using flow cytometer. n=4, 
**p<0.01, ***p<0.001. 
 The effect of our particle treatments on cytotoxic behavior was determined by 
measuring the CD107a expression using flow cytometry. CD107a expression was 
significantly increased as a result of anti-CD3/28 Dynabeads (p<0.001) compared to anti-
CD3, anti-CD28, and anti-CD3/28 particles, which displayed no difference between these 
conditions and only elicited a significantly greater percentage of cells expressing CD107a 
than untreated primary T cells (Figure 13A, p<0.0001). The direct effect of including 
anti-CD28 antibody on cytotoxicity was determined by incubating co-cultures of primary 
human T cells and cancer cells with anti-CD3, anti-CD28, 1:4 anti-CD3/28 particles or 
negative controls (Figure 13B). Our particle formulations that included anti-CD3 
antibody elicited significant primary T cell cytotoxicity in comparison to the untreated 
control (p<0.05) and further, treatment with the 1:4 anti-CD3/28 particle resulted in 
significantly more cancer cell death than anti-CD3/28 Dynabeads (p<0.05). Additionally, 
although not significant, anti-CD3 particles showed increased cytotoxicity compared to 
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anti-CD3/28 Dynabeads (p=0.0819) that could possibly become significant with an 
increase in sample size. These results suggest an interesting phenomenon in which anti-
CD3/28 Dynabeads cause more cells to release granules, but do not result in higher 
cytotoxicity – possibly, the magnitude of degranulation elicited from these commercial 
particles is less than that from our particle formulations. Taken together, these data show 
that while including anti-CD28 antibody on our particles has no impact on T cell binding 
or CD107a expression – and only slightly improved proliferation – this inclusion is 
critical for enhanced T cell cytotoxic responses. 
 
Figure 13: T cell Cytotoxicity from anti-CD3/28 Particles. (A, B) Co-cultures of T 
cells and cancer cells were treated with various particle conditions. (A) CD107a was 
stained using alexa fluor 488 anti-human CD107a and measured using flow cytometry. 
Data are represented at mean ± SEM, n=6; ***p<0.001, ****p<0.0001. (B) Cytotoxicity 
was measured via live/dead flowmetric assay. n=4; *p<0.05. 
3.4 Discussion 
Particles are routinely and extensively used by researchers for T cell activation in a wide 
variety of applications, including selecting and/or expanding antigen-specific T cells(169, 
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175, 194). Density of cellular signals and particle size critically affect the presentation of 
molecular signal(167, 195) and thus how T cells initiate activation and cytotoxic 
responses. Particle size and molecular density can induce tunable cellular behaviors(167) 
and modulate the immune system(167) in vitro; therefore, investigating the effect of 
particle size and molecular surface saturation on signal presentation offers valuable 
insight into modulating T cell processes. In this study we examine how presentation of 
molecular signals affects the biological activity of T cells to maximize activation and 
downstream cytotoxic effects. 
 Anti-CD3 antibody is widely used to non-specifically activate T cells, both 
immobilized and in soluble form, by engaging the TCR/CD3 complex to cause 
downstream induction of effector cell activation, proliferation, and cytotoxicity(196). Our 
results show that this activation response can be modified through changes in the particle 
size and conjugation densities. We successfully conjugated carboxylated particle surfaces 
using EDC with varying surface densities of anti-CD3 antibodies (Figure 1, Figure 2, 
Table 1). Antibodies are comprised of a highly conserved Fc region and two F(ab) 
regions which are responsible for binding specific antigens and thus are highly 
variable(170, 197). The Fc region is more hydrophobic than the F(ab) regions and will 
typically orient closest to the particle surface even with site non-specific conjugation 
schemes – orienting the F(ab)2 region outward(198, 199) to engage the TCR and initiate 
T cell activation. Increasing the conjugation density of anti-CD3 antibody should result in 
greater TCR engagement and thus increased activation responses. However, we 
unexpectedly determined that highest densities of anti-CD3 antibody resulted in less GrB 
secretion, and ostensibly, less T cell activation, as shown in Figure 3A. We postulate that 
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this reduced activation is related to the reduced accessibility of the anti-CD3 F(ab) 
regions; we determined that F(ab)2 region availability positively correlated with T cell 
activation (Table 2). As greater amounts of F(ab)2 region were available, greater 
concentrations of GrB were measured. The reasons for this decreased accessibility at high 
functionalization amounts are not clear. Previous studies in immunosorbance observed 
high immobilization densities of proteins resulted in reduced specific activity of that 
protein, most likely due to steric hindrance or slight denaturing due to overly dense 
antibody packing(200), to which the more conserved Fc antibody region is less 
susceptible. Additionally, the non-specific conjugation scheme may result in instances of 
misorientation that amplify at higher conjugation densities. This possible denaturation or 
misorientation may explain why the anti-CD3 Fc region availability continues to increase 
as the conjugation density also increases (Figure 3A). Additionally, our study 
investigates anti-CD3 antibody accessibility to large, whole-protein antigens, either 
fluorescent secondary antibodies or T cell receptor complexes, and anti-CD3 antibody 
accessibility to such antigens is innately low and thus susceptible to binding site 
obstruction due to steric hindrance and misorientation(195). We speculate that these 
factors contribute to the corresponding GrB secretion and F(ab)2 region accessibility 
peaks at 25 μg (0.3 and 1.0 μm) or 50 μg (3.0 μm), and the restricted F(ab)2 region 
availability at the higher particle surface coverages. From these data, we can conclude 
that maximal T cell activation will most likely occur when the anti-CD3 antibody F(ab)2 
region is most available for interaction with immune cells. 
Delivering equivalent anti-CD3 antibody on particles of different sizes reveals a 
clear size-dependency of T cell activation, in which small (0.3 μm) particles produced 
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significantly higher GrB concentrations from T cells than larger (3.0 μm and 1.0 μm) 
particles (Figure 3B). Smaller particles have been shown to bind more frequently to 
cells(201), which would increase activation in our application and produce higher 
immune responses than larger particles(167, 171). Our data are consistent with prior 
research that show larger particles can induce higher T cell activation responses(202), but 
when equivalent amounts of anti-CD3 are controlled, the trend reverses. This could be a 
result of the higher curvature innate to the geometry of smaller particles or increased 
number of initiation sites on the cell. This higher curvature of 0.3 μm particles may result 
in greater accessibility of TCR binding region of anti-CD3 antibodies to TCR/CD3 
complexes on T cells, especially given the large antigen size(167, 195), and therefore 
elicit greater T cell activation. This result demonstrates that dosing T cells with 0.3 μm 
and 1.0 μm particles did not result in significantly more GrB release than their respective 
0 μg controls at lower concentrations (Figure 2A). Therefore we can conclude that 
smaller particles trigger greater T cell activation at relevant doses. 
Based on these data, we selected to use the 0.3 μm particle conjugated with 25 μg 
of anti-CD3 antibody (corresponding to 41% particle surface saturation, Table 1) for 
further study. Greater GrB secretion was measured when particles were used to deliver 
anti-CD3 or anti-CD3/28 antibody to T cells, compared to equivalent soluble antibody, 
most likely due to the dense presentation of stimulating molecules that are present on 
particle surfaces. It is possible for these particles to bind strongly to T cells through 
multivalent interactions(166), thus eliciting a high immune response (2, 15, 18); whereas 
soluble anti-CD3 antibody will activate T cells only through many mono- or bivalent 
interactions from numerous antibodies, resulting in less crosslinking and thus less 
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activation. This multivalent advantage leads not only to greater activation (Figure 4), but 
greater cytotoxicity; cytotoxicity studies determined that anti-CD3 particles induced 
significantly greater T cell cytotoxicity compared to equivalent dosing with soluble 
antibody (Figure 5). The correlation between T cell activation and downstream 
cytotoxicity was calculated (Figure 6) and we found a positive association between the 
two data sets, indicating that greater T cell activation may lead to similarly higher 
cytotoxicity. Interestingly, while there was no significant difference in the amount of GrB 
secreted by T cells or the proliferation of primary human T cells following incubation of 
anti-CD3/28 Dynabeads and anti-CD3 particles (Figure 4), we found Dynabead 
treatment resulted in significantly less cytotoxicity than anti-CD3 particles (Figure 5A-
B). However, primary T cell CD107a expression – a marker of degranulation – was 
significantly increased on Dynabead-treated cells compared to our anti-CD3 particles 
(Figure 5C). The mechanism behind these results – similar GrB secretion, decreased 
cytotoxicity, and higher CD107a expression compared to our anti-CD3 particles – has not 
been fully elucidated, but particle size, unknown antibody labeling density and 
patterning, and dosing likely contribute to the observed effect. Anti-CD3/28 Dynabeads 
are 15x larger than our optimal anti-CD3 particles (Figure 3B) and, based on our 
previous findings regarding particle size, should result in less immunogenicity. 
Furthermore, T cells were dosed with Dynabeads according to the manufacturer’s 
protocol, whereas anti-CD3 particle doses were optimized based on an optimization 
experiment (Figure 14). Although not likely, it is possible that including co-stimulation 
with anti-CD28 antibody on Dynabeads reduces the amount of anti-CD3 antibody 
presented, and therefore reduces cytotoxicity in comparison to anti-CD3 only particles. 
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Figure 14: Particle Dosing. Cultures of Jurkat and cancer cells were dosed with 
increasing amounts of anti-CD3 particles and then assessed for cytotoxicity using a 
live/dead assay. Data are represented as mean ± SEM, n=4; **p<0.01, ***p<0.001, 
****p<0.0001. 
To explore the effect of our anti-CD3 particles have on T cell and cancer cell 
interactions, a necessity for conventionally native T cell cytotoxicity, three different 
experimental designs were examined: conditioned media, where cancer cells are treated 
with the supernatant of particle-activated cytotoxic T cells; transwell, in which a porous 
membrane separates cancer and T cells with anti-CD3 particles; and direct co-culture, in 
which particles and all cell types are present in the same culture space to freely allow 
physical contact between cancer and immune cells (Figure 9). The designs allow for 
different degrees of interaction between cell types, over time and distance. Direct co-
culture experiments resulted in significantly more cancer cell death than conditioned 
media and transwell constructs, indicating that the freedom for T cells to interact with 
cancer cells is critical for the significant killing of cancer cells. The necessity of cell 
interactions for effective cytotoxicity is not surprising; cytotoxic T cells become activated 
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in the native immune milieu when bound to target cells and, once activated, secrete 
cytolytic granules proximally and with high directionality across nanometers of 
extracellular space(203). Cancer cells then receive a highly localized and concentrated 
dose of perforin and granzymes, thereby initiating an apoptotic signaling cascade. 
Without this concentrated dose, as demonstrated with conditioned media and transwell 
conditions, significant cytotoxicity is not likely. It is possible that the need for a highly 
concentrated dose is why Dynabeads elicit less cancer cell death, despite similar T cell 
activation responses (Figure 4) and evidence of high T cell cytotoxicity (Figure 5C); the 
larger Dynabead may separate the T cell and its cognate cancer cell such that it interferes 
with cytolytic granule diffusion, resulting in lower cytotoxic cancer cell death. Further 
studies will be necessary to investigate this hypothesis. We can conclude, however, that 
the ability of our anti-CD3 particles to promote close T cell interaction with cancer cells 
is crucial for effective cytotoxicity against cancer cells. 
Anti-CD3 antibody has been studied extensively alone and with anti-CD28 
antibody as a co-stimulatory molecule due to its ability to activate T cells non-
specifically. However, using anti-CD3 antibody to non-specifically activate T cells has 
been shown to be problematic; without a co-activation signal (e.g. CD28), anti-CD3 only 
activated T cells will usually become less functional or undergo apoptosis(192). To 
stimulate T cells in vitro, researchers typically use commercially available anti-CD3/28 
beads (in which the labeling density is proprietary) or functionalize with anti-CD3 and 
anti-CD28 antibodies in equivalent amounts(175, 190), resulting in 1:1 anti-CD3/28 
particles. This ratio is common practice due to the establishment that following activation 
through the TCR/CD3 complex, CD28 will associate with this macromolecule to promote 
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cell survival and upregulate cell metabolism on a one-to-one basis(188, 192). However, 
our results indicate that a 1:1 ratio of anti-CD3/28 antibodies does not elicit the highest 
amount of primary T cell proliferation (Figure 11B); cells incubated with particles 
containing higher ratios of anti-CD28 antibody to anti-CD3 antibody showed 
significantly increased proliferation compared to 1:1 anti-CD3/28 particles (p<0.05 at 
least). T cell binding studies further revealed that 1:4 anti-CD3/28 particles bound 
significantly more T cells than 1:2 anti-CD3/28 particles (Figure 11A). From these 
results, we selected 1:4 anti-CD3/28 particles for continued study. It should be noted that 
we investigated these particle effects on primary T cells, not only CD8+ T cells, so it is 
possible that a different ratio is more appropriate for CD8+ T cells only. However, given 
that the absolute values of our proliferation and T cell targeting assays for all particle 
conditions were fairly similar, we are confident that the effect of a precise CD8+ T cell 
anti-CD3/28 ratio should not be so large and distinct that our studies using a particle we 
optimized for T cells are divergent. 
While we had previously observed similar proliferation responses from human 
primary T cells due to anti-CD3 particle or anti-CD3/28 Dynabead treatment (Figure 4B 
and Figure 12B), anti-CD28 antibody significantly increased proliferation; this was 
observed for both 1:4 anti-CD3/28 and anti-CD28 particles (Figure 12B). The ability of 
anti-CD28 only particles to enhance proliferation is not well researched, but previous 
studies have shown that extensive CD28 crosslinking can induce T cell 
activation/proliferation(204, 205). However, this crosslinking did not translate into 
cytotoxicity (Figure 13). The inclusion of anti-CD28 antibody onto our anti-CD3 
particles does enhanced cytotoxicity though; 1:4 anti-CD3/28 particles elicited 
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significantly greater cytotoxic cancer death than anti-CD3/28 Dynabeads or the untreated 
control whereas anti-CD3 particle treatment resulted in increased cytotoxicity compared 
to untreated cells only (Figure 13). 
Interestingly, anti-CD3, anti-CD28, and 1:4 anti-CD3/28 particles bound to more 
T cells but resulted in significantly fewer cells expressing CD107a than did anti-CD3/28 
Dynabeads, which bound to significantly fewer cells (Figure 12A and Figure 13A). This 
suggests that anti-CD3/28 Dynabeads activate T cells more efficiently than our particles 
(anti-CD3, anti-CD28, and 1:4 anti-CD3/28). The reason for this inefficiency is unclear, 
but may be size- or patterning- related. Further binding studies are necessary. 
Understanding how particle size and molecular density of anti-CD3/28 antibodies 
conjugated to particles are important not only for preclinical T cell activation and 
expansion studies, but also for all particle-based immunotherapies, such as artificial 
antigen presenting cells(115). We anticipate our findings can translate to any biomaterial 
surface used to non-specifically or specifically stimulate T cells. These results are 
relevant not only for the in vitro activation of T cells, but they are also important for 
understanding the downstream effects following non-specific cytotoxic T cell activation 
by particles. While selecting and expanding T cells can be important for its own end, the 
functionality of those T cells against relevant target cells can be improved by optimizing 
the T cell proximity to target cells for effective cytotoxicity. Future investigations into the 
specific activation of T cells – replacing anti-CD3 with antigen or antigenic peptide 
presented in the context of MHC – will help us to better understand how the conclusions 
reached here effect antigen-specific T cell stimulation. Furthermore, the inclusion of 
cancer-binding moieties will also be examined. In summary, our optimized anti-CD3/28 
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particles improve upon existing and commercial methods for T cell activation and may be 
a powerful addition to the rational biomaterial design library for T cell cytotoxicity. 
3.5 Conclusions 
We have successfully demonstrated the effect of particle size, molecular density, and 
activating molecule on T cell activation and cytotoxicity. Decreasing particle size and 
optimizing surface coverage results in increased GrB release. T cell activation and 
cytotoxicity is also dependent on the activating molecule(s). Cytotoxicity studies showed 
that anti-CD3 particles were more effective than soluble antibody alone and demonstrated 
that immune cell proximity to cancer cells was responsible for cancer cell death. We 
conclude that 1:4 ratio of anti-CD3/28 displayed on small 300 nm particles represent a 
highly promising platform for T cell activation, expansion, or cytotoxicity in which 




CHAPTER 4. CHARACTERIZING THE BIOPHYSICAL T CELL 
ACTIVATION RESPONSE 
4.1 Introduction 
Immunotherapeutic treatments are increasingly showing great potential as effective 
cancer treatments(12, 98). Central to these strategies is reestablishing immune cell 
function within the tumor microenvironment; although immune cells regularly migrate to 
the tumor site, they cannot always mount a successful immune response due to 
immunsuppressive signals secreted and expressed by cancer cells(19). Artificial antigen 
presenting cells (aAPC) – particle- or particle-like platforms that mimic antigen 
presenting cells (i.e. dendritic cells) – are being investigated as a possible therapeutic to 
initiate an immune response to cancer(161, 175). The most common iteration of this 
overall strategy involves activating T cells, usually CD8+ T cells(173, 179). The 
activation of these cytotoxic T cells causes cytoltyic granule secretion. These granules 
contain perforin and various granzymes, which then trigger apoptosis in the targeted 
cancer cell. Thus, by activating CD8+ T cells within the tumor environment, an immune 
system driven anti-cancer response can eradicate the tumor. aAPCs have shown pre-
clinical success in this area(173, 179). Recent publications have emphasized aAPCs that 
are nanoscale(175) and biomimetic(181, 206); these strategies have resulted in robust T 
cell responses, including proliferation and expression of different activation markers(162, 
181, 206, 207). However, while activation markers such as proliferation, granzyme b 
secretion, and even immune synapse formation have been examined, researchers have not 
yet examined the effect of aAPCs on the biophysical activation response of T cells. 
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T cell activation affects cell motility, migration, and stiffness, among others – all 
of which are driven by changes in the cytoskeletal structure of the cell(208-210). 
Cytolytic granule secretion by cytotoxic T cells, especially, is only possible with a 
dynamic and responsive cytoskeleton(211). When CD8+ T cells are activated, immune 
synapses form due to extensive actin remodeling; signaling and adhesion molecules, such 
as CD3, CD8, LFA-1, and ICAM-1, are clustered together, so that activation signals are 
more strongly transduced and sustained(212). Microtubules rearrange, and the 
microtubule organizing center (MTOC) translocates to the immune synapse to guide 
cytolytic granules to release in a highly directional manner toward its bound cognate 
cell(211, 213). Immune synapse formation by activated T cells introduces asymmetry 
within the cell, concentrating actin, microtubulin, and various signaling proteins within 
particular areas of the cell, instead evenly distributed over the whole cell. 
The immune synapse has been extensively studied and has been implicated in a 
variety of processes, including TCR signaling(209), cytokine or cytolytic granule 
release(211), and T cell polarity(214). However, the broader implications of T cell 
activation from particle-based immunotherapies and the subsequent formation of the 
immune synapse on mechanics of the whole cell is not fully understood nor well studied. 
Whole cell mechanics – stiffness, viscosity, motility – can give insight into cell behavior, 
such as migration, or be used as phenotypic biomarker. In this study, we evaluated the 
biomechanical response to our 0.3 μm anti-CD3 and anti-CD3/28 particles. We 
investigated immune synapse formation and correlated it with T cell polarity resulting 
from cytoskeletal rearrangement. This cytoskeletal remodeling also seems to be 
responsible for the measured cell softening and faster relaxation time we observed from 
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AFM studies. T cell activation reduced cell motility but increased cancer cell binding, 
indicating this treatment would be most effective within the tumor microenvironment. 
4.2 Materials and Methods 
4.2.1 Cell Culture 
Primary human CD8+ T cells were cultured in RPMI 1640 cell culture media (ATCC, 
Manassas, VA) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals; 
Norcross, GA) and 1% penicillin-streptomycin (Sigma Aldrich, St. Louis, MO) and 
maintained between 1 x 10
5
 and 1 x 10
6
 cells/mL. CD8+ T cells were isolated from 
peripheral human blood using EasySep CD8+ T cell Isolation Kit (Stem Cell 
Technologies; Vancouver, Canada). The human ovarian cancer cell lines HeyA8 was 
gifted from the McDonald laboratory (Georgia Institute of Technology, Atlanta, GA). 
HeyA8 monolayers were cultured using the same cell growth medium as the T cells were 
passaged after flask confluency reached at least 70%. All cells were maintained at 37 °C 
with 5% CO2. All cells used were below passage 30 with viability assessed using trypan 
blue. 
4.2.2 Particle functionalization 
0.3 μm silica particles (Bangs Laboratories, Fishers, IN) were conjugated with anti-CD3, 
anti-CD3/28 antibodies (Biolegend, San Diego, CA), or BSA (Sigma Aldrich, St Louis, 
MO) as a control, using APTES  silanization, as described previously(215). Briefly, silica 
particles were washed with acetone, and then incubated for two min at room temperature 
with a 2% APTES (Sigma Aldrich) solution. Particles were then washed twice with dd 
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H2O and heated to complete the silanization process. Particles were then incubated with 1 
mg/mL anti-CD3 and anti-CD28 antibodies for 1 hour at room temperature on an end-
over-end spinner. Finally, particles were washed twice with PBS and stored at 8 ⁰C. 
4.2.3 Immune synapse formation 
CD8+ T cells were treated with anti-CD3 and anti-CD3/28 particles, as well as particles 
labeled with control protein, and incubated for 1 hour at 37 ⁰C with 5% CO2. Following 
incubation, cells were deposited onto Cell Tak coated coverslips and centrifuged at 300 x 
G for 3 min to cause cell adhesion. To image the formation of the immune synapse, cells 
were fixed with 4% PFA (Sigma Aldrich), permeabilized with 0.1% Triton-X (Sigma 
Aldrich), and labeled with alexa fluor 488 anti-human LFA-1 (ThermoFisher Scientific, 
Waltham, MA) and alexa fluor 647 anti-human Mac-1 (VWR, Radnor, PA). Cells were 
imaged using at 63x (Plan Apochromat 1.4 NA oil) using a Leiss LSM 700 scan head 
mounted on an AxioObserver Z1 inverted microscope stage. Approximately 50 cells were 
imaged per condition from three independent experiments. 
4.2.4 AFM 
AFM nanoindentation was performed on an Asylum Research MFP3D AFM (Santa 
Barbara, CA), mounted on an inverted Nikon Eclipse Ti (NIKON DETAILS) at 20x and 
run with Asylum 12. Bruker MCLTO-10 AFM tips were manually beaded with a 4.47um 
diameter polystyrene bead. Before each experiment, the tip’s spring constant was 
calibrated using indention against glass surfaces and Asylum’s thermal fluctuation 
method. Individual T cells were prepared in a FluoroDish (World Precision Instruments, 
Sarasota, FL) following a three hour incubation with BSA or anti-CD3/28 particles. Cells 
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were indented at 2um/s up to 2nN and then the tip was programmed to dwell at a fixed 
indention for 3 seconds before retracting. An image of each cell was collected for image 
processing as described elsewhere. Young’s modulus was calculated using a custom 
Matlab (TheMathWorks, Waltham, MA) script, which zeroed the force and indention 
data about the contact point reported by Asylum’s software and then used a linearized 
force curve approach with a Poisson’s ratio of 0.5 to estimate the modulus. Viscous 
relaxation was fit using a two-parameter relaxation model on contact and force data, also 
in Matlab.  
4.2.5 Cytoskeleton arrangement 
F-actin and α-tubulin was imaged following T cell activation with particles. Briefly, 
1x10
6
 cells/mL CD8+ T cells were incubated with BSA or anti-CD3/28 particles for three 
hours at room temperature on an end-over-end spinner. Stimulated T cells were spun 
down onto glass coverslips or glass bottom 35 mm dishes coated with Cell Tak (Corning, 
Corning, NY). For F-actin staining, cells were fixed with 4% PFA for 10 min. Cells were 
washed twice with PBS (ThermoFisher Scientific) and permeabilized using a 0.1% 
Triton-X solution for 10 min at room temperature. Phalloidin Alexa Fluor 647 
(ThermoFisher Scientific) was prepared in PBS according to the manufacturer’s 
instructions and administered to T cells for 20 min in the dark. After staining, cells were 
washed and counter stained with DAPI (ThermoFisher Scientific) for 5 min before 
mounting onto glass microscope slides. Microtubulin organization was visualized in live 
cells using Tubulin Tracker Green (ThermoFisher Scientific). Briefly, T cells were 
incubated with the tubulin stain for 30 min at 37 ⁰C, prepared according the 
manufacturer’s instructions. All cells were imaged at 63x using confocal microscopy. 
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Live cell imaging utilized a CO2 incubation chamber such that a 5% CO2 environment 
was maintained. At minimum, 85 cells were imaged per condition from three separate 
experiments for the live tubulin imaging, and 35 cells from three experiments for actin 
imaging. 
4.2.6 T cell motility 
6 well plates were coated with 5 μg/mL fibronectin at 37 ⁰C for 1 hour and then washed 
with PBS. Purified T cells were resuspended in Live Cell Imaging buffer (ThermoFisher 
Scientific) and allowed to settle for one hour before imaging. Image acquisition was 
conducted on an epifluorescent microscope (TE; Nikon Instruments Inc, Melville, NY) 
using a 10x objective. Brightfield images were acquired every 5 s for 15 min using Nikon 
NIS-Elements software (Nikon Instruments Inc) and T cell motility was quantified using 
the cell tracker plugin of Image J. Track length is defined as the total distance traveled by 
each cell and displacement is defined as the distance between the between the first and 
last position of the cell. 
4.2.7 T cell-cancer cell binding 
The effect our particle treatment has on T cell and cancer cell interactions was assessed 
by time-lapse live cell imaging. We plated 1.0 x 10
4
 cells/mL HeyA8 cells into 24 well 
culture plates, allowed them to adhere for 24 hours, and then seeded an equivalent 
number of Jurkat cells and dosed with our anti-CD3 and anti-CD3/28 particles, soluble 
anti-CD3, BSA particles, or left untreated. Co-cultures were allowed to incubate for one 
hour and then the plate was transferred to the BioTek Cytation 3 Imaging plate reader 
(BioTek Instruments, Winooski, VT). Bright field images of each well were taken at 10x 
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magnification every three minutes for four hours using the Gen5 software (BioTek 
Instruments). The plate was shaken after each cycle of imaging to displace non-bound T 
cells. During this time, cells were maintained at 37 ⁰C and 5% CO2. Binding events and 
duration was quantified by observing differences between frames. A cell was evaluated 
as bound if the Jurkat cell moved less than 5 μm and the interaction lasted for two or 
more frames. 
4.2.8 Statistical Analysis 
Statistical analysis was conducted in Graphpad Prism (La Jolla, CA) using one way or 
two-way ANOVA to determine significance of variables. Post-hoc Tukey-Kramer HSD 
testing was performed to determine significance. Data are represented using mean ± 
SEM. 
4.3 Results 
4.3.1 Immune synapse formation 
T cells accumulate a number of signaling and adhesion molecules in the contact area with 
its cognate cell, eventually forming an immune synapse. Mature immune synapses 
contain a cluster of activation molecules, including TCR/CD3 and CD28, surrounded by 
a dense ring of adhesion molecules, such as LFA-1(216). To study the ability of our 
particles to trigger immune synapse formation, we incubated T cells with anti-CD3, anti-
CD3/28, or control protein particles. Representative images of each condition are shown 
in Figure 15. A no particle condition was included as a negative control. T cells were 
stained for LFA-1 and Mac-1 and analysed using confocal microscopy. In the absence of 
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anti-CD3 antibody on particles, most T cells displayed an equal distribution of LFA-1. In 
contrast, anti-CD3 and anti-CD3/28 particles elicited clustering of LFA-1 on the T cell 
surface, with anti-CD3/28 particles displaying an increased clustering response compared 
to the anti-CD3 only particles. Although Mac-1 is present on all T cells, its expression is 
upregulated in the immune synapse of newly activated T cells(217); thus the 
accumulation of Mac-1 into a particular area of the cell is characteristic of immune 
synapse formation. Like LFA-1 clustering, the inclusion of anti-CD28 antibody onto the 
particle greatly increased the signal we observed. Unfortunately, we could not 
characterize the locations of formed immune synapses with bound particles as our 300 
nm particles are too small to be clearly identified in bright-field images. 
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Figure 15: Immune Synapse Formation. CD8+ T cells were incubated alone or with 
BSA, anti-CD3, or anti-CD3/28 particles for one hour, after which cells were fixed, 
permeabilized, and stained for LFA-1, Mac-1, and the nucleus. Scale bar = 5 μm. 
4.3.2 Cytoskeletal Arrangement 
To further elucidate how our particles affect T cell immune synapse formation and the 
underlying activated T cell mechanics, we investigated the arrangement of two 
LFA-1    Mac-1   Nucleus 
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cytoskeletal molecules, F-actin and α-microtubulin. Actin accumulates at the immune 
synapse and microtubules will reorganize such that the microtubule organizing center 
(MTOC) translocates near the immune synapse(213). In the case of CD8+ T cells, 
microtubules direct cytolytic granules to be secreted in a highly direction manner, from 
the immune synapse toward the bound, cognate cell(211). To ensure cells were binding to 
particles and thus initiating immune synapse formation, T cells were incubated with 
particles for one hour before labelling cells for either α-tubulin or F-actin. In comparison 
to our no particle and BSA particle conditions, anti-CD3 and anti-CD3/28 particles 
demonstrated a high degree of cell polarity, in which a high cytoskeletal signal was 
observed to be concentrated at certain region in the cell (Figure 16). This polarity was 
enhanced when anti-CD28 antibody was included on each particle. The negative control 
T cells displayed an even expression of F-actin and α-tubulin within the cell. 
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Figure 16: Cytoskeletal Arrangement. T cells were incubated with BSA, anti-CD3, and 
anti-CD3/28 particles for three hours. F-actin staining was performed following 
paraformaldehyde fixation and permeabilization. T cells were also stained with DAPI. 
Live cells were stained for α-tubulin using phalloidin 488. Cells were imaged and 
analyzed to count cells that contained either polarized or diffusive cytoskeletal 
arrangements. Scale bar = 5 μm. F-actin is quantified on the left and α-tubulin is 
quantified on the right. 
4.3.3 AFM 
Cell stiffness and viscosity changes following T cell activation with anti-CD3 or anti-
CD28 particles were measured using AFM. T cells were incubated with activating or 
protein control particles, as well as no particles, for one hour and then allowed to adhere 
to a coverslip coated with Cell Tak. Fluor dishes containing live cell imaging solution 
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were used to perform these measurements. Brightfield images of cells were taken 
following force measurements to measure T cell size. As shown in Figure 17C, T cells 
were only significantly different sizes when we compared our fixed PFA control to our 
BSA control particle condition. 
  
Figure 17: Mechanical Properties of anti-CD3/28 Particle-Activated T cells. Atomic 
force microscopy was used to measure Young’s Modulus (A) and determine the 
viscoelastic properties of activated or unactivated T cells (B). Images of each measured 
cell were taken and the T cell diameter calculated (C). Data are represented as mean ± 
SD. *p<0.05, **p<0.01, ****p<0.0001. 
Figure 17A shows that T cells activated using anti-CD3/28 particles exhibit a 
significantly lower Young’s Modulus compared to unactivated T cells (p<0.05). These 
stiffness results reflect the elastic properties of activated (or non-activated) T cells. 
However, as cells also contain a viscoelastic component, examining these parameters by 
altering AFM measurements can give further insight into the cellular mechanics of 
activated T cells. Figure 17B shows that while there is no difference between our 
conditions when we measure the fast relaxation constant and the force ratio between the 
fast and slow relaxation constants, the slow relaxation constant does demonstrate 
significant differences between activated and naïve T cells. T cells activated with anti-
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CD3/28 particles displayed a significantly smaller slow relaxation constant, indicating 
that over longer time spans, activated T cells relax faster. The exact mechanism behind 
slow and fast relaxation times – and in fact, the general mechanisms responsible for 
viscoelastic properties in cells – is the subject of much debate. Cytosol flow within the 
cell(218), cytoskeleton arrangement and rigidity(219), and the plasma membrane(220) 
are all thought to contribute to viscoelastic behavior, but research investigating these 
factors in an isolated manner is still necessary before additional conclusions may be 
reached.  
4.3.4 T cell Motility 
When naïve T cells are activated by APCs in vivo, a cascade of events is triggered, 
typically including clonal expansion, differentiation, and migration to the disease 
location(221). Since activated T cells show a softened and pliable cytoskeleton, we 
hypothesized that T cell motility would increase as T cells interact more readily with their 
environment and search for their cognate cells. However, as our data show in Figure 18, 
activated T cells actually travel a shorter distance in vitro (Figure 18A-B) and move more 
slowly compared to their non-activated counterparts (Figure 18C). This result may be 
influenced perhaps by the ligand used to coat dishes; fibronectin is expressed during 
inflammation, and naturally bind more readily to activated T cells compared to non-
activated T cells, which may have increased cell adhesion and thus arrested motility(222). 
Furthermore, as no chemokine gradient was present to encourage T cell migration in a 
particular direction, activated T cells had no motivation to continue moving after binding 
to a relevant adhesion molecule like fibronectin. This observation was further 
investigated by examining T cell infiltration within cell spheroids in CHAPTER 5. 
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Figure 18: T cell Motility. T cells were incubated in fibronectin-coated dishes for one 
hour and imaged for motility over 15 minutes, at a frame rate of one image every 5 s. 
Data are represented as mean ± SEM; n=7, *p<0.05, **p<0.01, ***p<0.001, p<0.0001. 
4.3.5 T cell-cancer cell binding 
T cell and cancer cellular interactions post-treatment were evaluated using live cell 
imaging over four hours, as shown in Figure 19. T cells treated with anti-CD3 and anti-
CD3/28 particles displayed increased interactions with cancer cells, binding more 
frequently than untreated co-cultures (p<0.05). Anti-CD3 particle-activated T cells also 
bound to cancer cells for a longer duration than untreated T cells or T cells treated with 
BSA-labeled particles (p<0.05). However, anti-CD3/28 particles caused T cells to bind to 
cancer cells for a significantly longer time (p<0.0001). This is most likely due to the 
presence of anti-CD28 antibody, which enhances activation and cognate cell binding. 
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Figure 19: Cell-Cell Binding. Cancer cells were seeded into wells and allowed to adhere 
for 24 hours. Jurkat cells and particles were added and allowed to incubate for one hour 
before imaging. Images were taken every three minutes for four hours. Number and 
duration of T cell binding events were calculated (c). n=8; *p<0.05, ****p<0.0001, 
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#p<0.05 with student t-test against untreated condition, p<0.05 with student t-test 
against BSA particles. Scale bar = 200 μm. 
4.4 Discussion 
The biophysical response of T cells to stimuli gives critical insight into activated T cell 
behavior, which is significant when designing activation platforms for these cells. For 
example, there is an understanding that leukocyte stiffness may be modulated by the 
immune system to mediate trafficking – that softened leukocytes more readily enter and 
stay in circulation(223). Additionally, it is known that TNF-α and IL-1β cause leukocytes 
to stiffen(210, 224), demonstrating that the inflammatory cytokines secreted by cancer 
cells promote a mechanical phenotype in T cells that make them less likely to respond in 
an anti-cancer fashion. Understanding these processes can inform the mode and location 
of delivery for immunomodulatory biomaterials as well as the size, multivalency, and 
stiffness of these materials – factors that heavily influence the degree of activation even 
possible(225, 226). For example, activating a CD8+ T cell away from the tumor 
microenvironment can negatively affect its ability to migrate. Thus, elucidating the 
biophysical implications of T cell activation in response to immunomodulatory particles 
is an important consideration when designing these platforms. 
In this study, we investigated the effect of aAPC stimulation on T cell activation 
and examination of the biophysical response. T cells stimulated with anti-CD3 and anti-
CD3/28 particles formed immune synapses (Figure 15) and also underwent substantial 
cytoskeletal remodeling that drives immune synapse development (Figure 16). 
Cytoskeletal accumulation at the immune synapse(s) of activated T cells, as demonstrated 
by us and others, has significant consequences on a variety of T cell properties. First, 
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activated T cells were less stiff than their unactivated counterparts and showed faster 
relaxation after compression, despite the increased volume of F-actin measured in 
activated T cells (Figure 16, Figure 17). Cell softening is traditionally associated with 
non-aligned, discontinuous F-actin(223, 227). So while more F-actin is present in 
activated T cells, its polarization is consistent with cells become softer, not stiffer. 
It has been recently suggested that the cytoskeleton in activated T cells is more 
pliable and thus able to respond more dynamically over a short time – a critical feature 
for immune synapse formation and associated downstream cellular activity(209). A less 
rigid cytoskeleton enhances the ability of actin to remodel, which affects the size and 
signaling intensity of the immune synapse. The increased pliability of the actin network 
in activated T cells may further correlate with membrane flexibility which is especially 
important in CD8+ T cells, as these effector cells will spread over their target cells, 
exhibiting large deformations so that large contact areas between T cells and their 
cognates are possible(209). The ability of T cells to deform is also important for 
extravasation and the increased pliability of activated T cell cytoskeletons is likely a 
contributing factor to the fast relaxation time we observed from the AFM measurements 
(Figure 17). Additionally, the accumulation of F-actin and α-tubulin at the immune 
synapse, instead of distributed evenly throughout the cell, could further allow for faster 
relaxation. 
It should be noted that costimulatory signaling through CD28 mediates cell 
softening, which is why our anti-CD3/28 particles elicit greater T cell activation, immune 
synapse formation with associated cytoskeletal remodelling, and softening compared to 
anti-CD3 only particles. These results suggest that anti-CD3/28 particle engagement 
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induces signaling through CD28 on the T cell, and amplifies the overall activation signal. 
However, previous studies have shown that CD28 engagement alone is not enough to 
fully activate T cells, so signaling through CD28 cannot be directly responsible for 
increased T cell activation(224). Instead, CD28 must work primarily as an amplifier for 
signaling through TCR/CD3 engagement. 
When we performed live cell imaging studies to examine the binding behavior of 
T cells activated with anti-CD3 and anti-CD3/28 particles, we observed that in 
comparison to the untreated or control protein particle conditions, the activated T cells 
bound to cancer cells more frequently and for greater duration (Figure 19). Since reduced 
cell motility was observed from activated T cells (Figure 18), we originally hypothesized 
that activated T cells would exhibit a more motile phenotype, with enhanced rates 
migration, searching for a cognate cell. We observed that activated T cells traveled less 
distance and were slower than non-activated T cells, possibly due to activated T cells 
binding more frequently and for a longer duration to fibronectin, a protein T cells would 
typically bind in vivo. This coupled with evidence that upon adhesion, cells typically stop 
migratory behavior(228, 229), gives reason to why activated T cells exhibit less motility 
than unactivated T cells. Additionally, studies have demonstrated that sustained T cell 
activation inhibits crawling by blocking shape change and new edge formation and 
causes membrane spreading over its cognate cell(209, 214, 230, 231). Since cell motility 
depends on large changes within the actin and microtubule structure(208, 232) – T cell 
activation would inhibit additional cytoskeletal remodeling beyond immune synapse 
formation. Thus, once T cells are activated, they are primed to bind to other cells. 
4.5 Conclusions 
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In conclusion, this work suggests that aAPCs are suitable for activating T cells within the 
tumor microenvironment. Our anti-CD3/28 particles – and to a lesser extent, our anti-
CD3 particles – cause immune synapses to form and reduce cell stiffness – events driven 
by considerable cytoskeleton remodeling due to T cell activation. Changes in 
biomechanical properties influence T cell behavior, reducing T cell motility and 
increasing T cell binding to cancer cells. Our work presented here suggests that aAPCs 
would optimally be administered primarily to resident CD8+ T cells within the tumor 
microenvironment to take advantage of resident immune cells. Future studies involving 
signaling and adhesion antibody patterning on aAPCs, to mimic the immune synapse – 
similar to studies performed previously by the Yu Laboratory(181), may amplify the T 
cell activation response as reported using flat, 2D surfaces. Because the TCR is small and 
has a low affinity toward antigen, presenting activating proteins in a particular way may 
increase the biophysical activated T cell response presented in this study(233). 
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CHAPTER 5. EVALUATE THE EFFECTS OF SPATIALLY 
SEGREGATING BIOLOGICAL SIGNALS ON T CELL – CANCER 
CELL CROSSLINKING AND DOWNSTREAM CYTOTOXICITY 
USING JANUS PARTICLES 
5.1 Introduction 
CD8+ T cells are effector immune cells which recognize antigens on cancer cells (and 
other pathogenic cells), bind strongly to these cells, and secrete cytolytic granules 
containing perforin and various granzymes to the bound cancer cell in a highly 
directional manner(4). The secretion cause the target cell to undergo apoptosis and die. 
The ability to activate these cells in vivo within the immunosuppressive tumor 
microenvironment is critically important for cancer treatment, as the presence and 
activity of these cells within patient tumors has shown to be associated with better 
clinical outcomes(20). Activating CD8+ T cells in vitro is thus a key step for many 
immunotherapies. Priming an effector T cell response in patients against a specific cancer 
antigen using antigen presenting cells (APCs) is costly, time consuming, varies widely 
between patients. To address these issues, researchers have developed artificial APCs 
(aAPCs) to activate T cells in a more standardized manner. aAPCs display either anti-
CD3 antibody or antigenic peptide-MHC complex for unspecific or specific activation, 
respectively, typically combined with co-stimulatory molecule anti-CD28 antibody. 
Antigen-specific priming of naïve T cells can be difficult, with the need for repeated 
stimulation and prolonged culturing, as relatively few antigen specific T cells are 
available(234). Researchers have solved this problem by either enhancing activation 
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responses through optimizing particle size, shape, and multivalency or by nonspecifically 
activating T cells(161). But non-antigen specific activation can result in unregulated T 
cell activation, leading to healthy tissue damage or even autoimmune disease. We 
hypothesize the inclusion of a cancer-targeting ligand coupled physically to the T cell 
activation, we can effectively extend tumor cell specificity to each aAPC. 
Janus particles, bifunctional particles with biologically or chemically distinct 
hemispheres, have a wide range of possible applications, particularly as therapeutic 
agents(173, 181, 215). Janus particles are innately multifunctional and maintain a highly 
dense and localized presentation of each signal that is impossible on traditional 
heterofunctional particles, thereby allowing for strong and simultaneous targeting and 
therapeutic behavior. Concentrated signal is important to enhance cellular 
responses(166); this is true especially with T cell activation, in which increased calcium 
signaling was observed when anti-CD3 antibody was clustered, as opposed to uniformly 
distributed across particle surfaces(173). While biological Janus particles have been used 
activate T cells(173, 181, 182), study phagocytosis(183-185), and kill cancer cells(235, 
236), there has been no research thus far in which both hemispheres are used to elicit 
biologically unique behaviors from different cells. In this study, we have functionalized 
Janus particles to activate CD8+ T cells and bind specific cancer cells concurrently. 
Using a technique previously published by the Sulchek lab(215), we conjugated anti-CD3 
and anti-CD28 antibodies onto the silica base hemisphere and anti-folate receptor (FR) 
antibody onto the gold-coated hemisphere of each Janus particle. We found that Janus 
particles are capable of activating T cells, targeting cancer cells, and thus enhancing T 
cell- cancer cell crosslinking and downstream cytotoxicity. Although silica particles 
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uniformly functionalized with all three molecules do produce an anti-tumor effect and 
contribute towards T cell infiltration, Janus particles significantly increased cytotoxicity 
of the targeted cells. 
5.2 Materials and Methods 
5.2.1 Cell Culture 
The human ovarian cancer cell lines HeyA8 and Ovcar-3 were gifted from the McDonald 
laboratory (Georgia Institute of Technology, Atlanta, GA). HeyA8 and Ovcar-3 
monolayers were cultured using RPMI-1640 cell culture media (ATCC, Manassas, VA) 
supplemented with 1% penicillin-streptomycin (Sigma Aldrich, St. Louis, MO) and 10% 
and 20% FBS (Atlanta Biologicals; Norcross, GA), respectively. Human dermal 
fibroblasts, hDF, were gifted from the Nerem laboratory (Georgia Institute of 
Technology, Atlanta, GA) and cultured using DMEM (Cellgro; Corning, Corning, NY) 
supplemented with 1% penicillin-streptomycin, 10% FBS, and 1% L-glutamine 
(Invitrogen, Carlsbad, CA). CD8+ T cells were isolated from peripheral blood collected 
from human donors in the Waller laboratory (Emory University, Atlanta, GA) using a 
negative selection isolation kit (Stemcell Technologies, Vancouver, Canada). All cells 
were maintained at 37 ⁰C with 5% CO2. All cells used were below passage 30 with 
viability assessed using trypan blue. 
5.2.2 Particle functionalization 
Janus particles were fabricated as previously described in Tang et al. (2012). Briefly, 
0.296 μm silica particles were deposited onto clean glass slides in monolayers and then 
 80 
coated with a 20 nm gold layer following a 5 nm titanium adhesion layer at 2 Å/s using a 
metal evaporation process (CHA E-Beam Evaporator). Janus particles were removed 
from glass slides using sonication in deionized water and then filtered to remove gold 
debris. Gold coated silica particles were washed twice with PBS and then the silica 
hemisphere was silanized by washing the Janus particles in acetone and incubating with a 
2% APTES-acetone solution for 2 min, washing twice with DI water, and drying in the 
oven. The activated particles were then incubated with anti-CD3 and anti-CD28 
antibodies for one hour, crosslinking the antibodies with the silica surface only. Next, our 
Janus particles were incubated for 4 hours with 1mM biotin-PEG4-thiol (Nanocs, Boston, 
MA) to biotinylate the gold hemisphere. Complete functionalization was achieved by 
incubating the particles with anti-folate receptor (FR) antibody – streptavidin conjugates, 
thereby forming biotin-streptavidin complexes. Anti-FR antibody - streptavidin 
conjugates were produced using the Lightning Link streptavidin conjugation kit (Novus 
Biologicals, Littleton, CO). Later, functionalization using with anti-FR/E-cadherin 
antibody-streptavidin conjugates was assessed. 
Uniform silica particles were functionalized using the same silanization process to 
activate the silica particle surface as previously described. Surface-activated silica 
particles were incubated with a mixture of anti-CD3, anti-CD28 (Biolegend; San Diego, 
CA), and anti-FR antibodies (Santa Cruz Biotechnologies, Dallas, TX) to conjugate in a 
random arrangement. Protein control particles were functionalized with streptavidin 
(ThermoFisher Scientific) on both the silica hemisphere and following biotin-PEG-thiol 
activation of the gold hemisphere. Single-hemisphere control particles were also 
produced such that anti-CD3/28 antibodies were conjugated as usual using APTES 
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silanization. Following biotin-PEG-thiol functionalization on the gold hemisphere, 
particles were incubated with streptavidin for one hour. Anti-FR control particles were 
produced by conjugating streptavidin to the silica surface and functionalizing the gold 
hemisphere with streptavidin-anti-FR antibody conjugates. For ease of discussing, these 
control particles will be referred to as anti-CD3/28 J. and anti-FR J. particles, 
respectively. 
 For characterization purposes, anti-CD3/28 antibodies were replaced with FITC 
BSA (Sigma Aldrich, St Louis, MO) and alexa fluor 647 streptavidin (Invitrogen) was 
used to complete gold hemisphere functionalization following biotin-PEG-thiol 
conjugation. 
5.2.3 Particle characterization 
Particle surface functionalization and protein conjugation was characterized following 
each step of the complete functionalization process for both Janus and uniform particles 
using the tunable resistive pulse sensing (TRPS) principle (qNANO Gold; IZON, 
Cambridge, MA). Particles were suspended in a solution of filtered 0.02% tween 20 
(Signma Aldrich) in PSB (ThermoFisher Scientific) before measuring particle size 
distribution, surface change, and concentration. 
Janus particle multi-functionality and protein spatial segregation was confirmed 
using flow cytometry and confocal microscopy. Confocal microscopy (Zeiss; Obekochen, 
Germany) was used to visually demonstrate the discrete spatial segregation between 
different protein functionalization processes on the two hemispheres. This segregation is 
quantified by measuring mean fluorescence intensity (MFI) over each hemisphere on 
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each image. 20 images per condition were taken, at 63X magnification. Particle multi-
functionality was determined using a BD Acuri C6 flow cytometer (Franklin Lakes, NJ). 
At least 25,000 events were recorded per sample measured. 
5.2.4 Cell targeting 
The ability of Janus particles to target specific cancer cells was assessed by incubating 
particles – first at various anti-FR densities and then different particle formulations 
(uniform or Janus) – against different target cell types at 37 ⁰C for eight hours, on an end-
over-end spinner. To prevent cell adhesion, complete cell medium were supplemented 
with 0.5M EDTA (ThermoFisher Scientific). Following incubation, particles were stained 
with PE anti-mouse secondary fluorescent antibody (Biolegend) and analyzed for binding 
using flow cytometry. The ability of anti-FR particles to selective target Ovcar-3 cells 
was also visualized using confocal microscopy. Ovcar-3, HeyA8, and hDF cells were 
grown on coverslips to 80% confluency before staining with a red fluorescent probe (Cell 
Tracker Deep Red, Thermo Fisher Scientific). Green fluorescent particles were labeled 
with anti-FR antibody or streptavidin using the conjugation scheme just described, and 
incubated with the cells for eight hours before washing and staining with Hoechst. 
Coverslips were mounted onto glass coverslips and imaged using a Zeiss 700 confocal 
microscope. Particle binding image quantification was performed using Volocity 6.3 
Image Analysis software (Perkin Elmer, Waltham, MA). 
5.2.5 T cell activation 
CD8+ T cell activation was measured by fluorescently staining for the presence of 
CD107a, a marker of degranulation. Briefly, primary human CD8+ T cells were dosed 
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with the relevant treatment groups, incubated for 3 hours, and then assessed for FITC 
mouse anti-human CD107a (Biolegend) using flow cytometry. 
5.2.6 Cell binding and particle crosslinking 
 The target cell – cancer cell crosslinking capability of Janus particles was 
assessed using confocal microscopy. Cancer and T cells were labeled with cell tracker red 
and green, respectively, and then incubated with anti-CD3/28/FR Janus particles at 37 ⁰C 
in the dark. After two hours, each sample was spun down onto Cel1 Tak (Corning; 
Corning, NY) coated coverslips at 300 x G for 3 minutes. Adhered cells were 
fluorescently labeled with CellMask orange plasma membrane stain (ThermoFisher 
Scientific) and then fixed with 4% paraformaldehyde (Sigma Aldrich). Cells were 
counterstained with DAPI (ThermoFisher Scientific) and then mounted onto glass 
coverslips for confocal imaging. Janus control particles and uniformly coated particles, in 
addition to no particles, were also assessed. 
5.2.7 Co-culture cytotoxicity 
The ability of the Janus and control particles to elicit cancer cell death, due to activated T 
cell – cancer cell crosslinking, was evaluated with a live/dead fluorescent staining kit 
(Invitrogen; Eugene, OR). Forward and side-scatter was used to differentiate T cells from 
cancer cells. Ovarian cancer cells were plated, allowed to adhere for 8 hours to reach 
homeostasis, and treated with primary human CD8+ T cells and particles for 24 hours. 
Cells were then harvested, stained for viability, and analyzed using flow cytometry. At 
least 25,000 events were recorded for each sample. When investigating E:T ratios on 
cancer cell cytotoxicity, an increasing number of T cells were used with equivalent 
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particle doses. The targeted ovarian cancer cell type was varied so that cell-specific 
cytotoxicity due to Janus and non-Janus particle targeting could be evaluated. 
5.2.8 Spheroid Formation and Characterization 
Solid tumor spheroids were formed by seeding 5 x 10
3
 cells/well in 100 μL/well of 20% 
methylcellulose thickened RPMI-1640 media, supplemented with 15% BSA and 1% 
penicillin-streptomycin. All spheroids were grown in round bottom, ultralow attachment 
96 well plates (Corning; Corning, NY), and maintained at 37 ⁰C with 5% CO2 and rotated 
on an orbital shaker at 60 rpm. Tumor spheroids were used for functional assays 
following four days of culturing. Growth was monitored using phase contrast 
microscopy. To characterize spheroids, Ovcar-3 cells were stained red with Cell Tracker 
Deep Red (Thermo Fisher Scientific, Waltham, MA), and after four days of culture, 
imaged using a Zeiss 700 confocal microscope (Oberkkochen, Germany). Diameters of 
the spheroids were measured using ZEN imaging software from Zeiss, shown in Figure 
29, along with a representative image of the Ovcar-3 spheroid. 
5.2.9 Spheroid Cytotoxicity 
Spheroid cytotoxicity was determined using confocal microscopy, instead of flow 
cytometry, so we could examine where within the 3D architecture of the spheroid cancer 
cell death occurred. To examine complete cell death, unstained Ovcar-3 cells were grown 
into spheroids, treated with Janus and control particles, along with 5 x 10
3
 CD8+ T cells. 
After 24 hours, spheroids were stained using a live/dead staining kit with calcein AM and 
ethidium homodimer-1 for one hour. After which and nuclei were labelled with hoechst, 
and mounted onto glass coverslips for imaging. To examine T cell infiltration as a result 
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of particle treatment, Ovcar-3 cells were labeled withCell Tracker Deep Red 
(ThermoFisher Scientific) and CD8+ T cells were labeled with Cell Tracker Green 
(ThermoFisher Scientific) before treating with yellow dead cell stain (Thermofisher 
Scientific). Again, spheroids were mounted onto glass coverslips and imaged using 
confocal microscopy. 
5.2.10 In vivo biodistribution and toxicity 
BALB\c mice were used to evaluate particle biodistribution and toxicity due to particle 
treatment after 1 hour, 4 hours, and 24 hours. Briefly, mice were injected intravenously 
with 2.5 μg anti-mouse Janus or isotype control particles. PBS vehicle was also examined 
for some experiments. At the appropriate time point, mice were euthanized and the heart, 
lung, liver, kidney and spleen harvested and imaged for particle distribution. 
Biodistribution was also assessed after 72 hours; 1.25 μg Janus or control particle dose 
was used at this time point only. Systemic toxicity following particle treatment was 
evaluated by measuring the concentration of IL1-β, IL-2, IL-4, IL-6, INF-γ, and TNF-α 
present in serum using luminex (Life Technologies, Carlsbad, CA). To examine T cell 
activation, splenocytes were stained using PE/Cy7 anti-mouse CD3, APC anti-mouse 
CD4, FITC anti-mouse CD8, and PE anti-mouse CD69 (Biolegend) and fluorescent 
intensity was measured using flow cytometry. 
5.2.11 Statistical analysis 
Statistical analysis was conducted in Graphpad Prism (La Jolla, CA) using one way or 
two-way ANOVA to determine variable significance. Post-hoc Tukey-Kramer HSD or 
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Student T testing was performed to determine significant differences between conditions. 
Data are represented using mean ± SEM. 
5.3 Results 
5.3.1 Anti-Folate Receptor Functionalized Particles Preferentially Target Ovcar-3 
Cells 
To determine investigate the ability of anti-FR particles to specifically target Ovcar-3 
cells (a human ovarian cancer cell line over-expressing FR), anti-FR antibody was 
conjugated onto cells at densities previously explored in CHAPTER 3. As shown in 
Figure 20A, we found that the 25 μg particle condition elicited significantly higher 
Ovcar-3 cell targeting capability, than 0 and 12.5 μg conditions (p<0.01 and p<0.05, 
respectively). This antibody density was then selected to further study the ability to 
specifically target cells over-expressing folate receptor. HeyA8 and hDF (a human 
ovarian cancer cell line and an immortalized human dermal fibroblast cell line with 
constitutive FR expression) were used to investigate particle selective targeting. Ovcar-3 
cells were targeted by particles to a significantly greater extent than HeyA8 and hDF cells 
(Figure 20B, p<0.0001), as assessed by flow cytometry. Anti-FR particle binding was 
also assessed using confocal microscopy, which revealed that our particles preferentially 
target Ovcar-3 cells over HeyA8 cells (p<0.0001) (Figure 20C-D). While there was no 
difference in anti-FR particle interactions between Ovcar-3 cells and hDF cells according 
to our image analysis, it is impossible to differentiate between particle endocytosis and 
binding. Given that our flow cytometry data presented in Figure 20B exclusively 
measures particle binding, it is reasonable to attribute the lack of difference shown in 
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Figure 20D between Ovcar-3 and hDF cells to hDF cells endocytosing the anti-FR 
particles. 
 
Figure 20: anti-FR Particle Characterization. (A) Particles functionalized with various 
densities of anti-FR antibody were incubated with Ovcar-3 cells to optimize cell targeting 
capability. Data are represented as mean ± SEM, n=4; **p<0.01, *p<0.05. (B) Specific 
cell targeting was verified by incubating anti-FR particles with FR-expressing cells 
(Ovcar-3) and non-FR expressing cells (HeyA8, hDF). n=4; ****p<0.0001. (C, D) Target 
cells were seeded onto coverslips and treated with fluorescent anti-FR or BSA particles 
for 8 hours. Representative images of each condition are shown. Scale bar = 100 μm (C). 
Particle targeting was quantified by counting the number of particles per frame and 
normalizing by the number of cells per frame (D). n=4. 
5.3.2 Janus Particle Functionalization and Characterization 
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The Janus particle functionalization process, due to the many steps involved, required 
some optimization. We evaluated five different schemes, of which two yielded dually 
functionalized Janus particles. For the purposes of characterization, BSA was 
functionalized to the silica hemisphere and streptavidin was functionalized to the gold 
coated hemisphere. The schemes are as follows: 1) Silica: Plain silica particle, APTES 
silanization and BSA incubation; 2) Janus-1: Gold-coated Janus particle, APTES 
silanization and BSA incubation; 3) Janus-2: Gold-coated Janus particle, APTES 
silanization, BSA incubation, biotin-PEG-thiol functionalization, and streptavidin 
incubation; 4) Janus-3: Gold-coated Janus particle, biotin-PEG-thiol functionalization 
and streptavidin incubation; 5). Janus-4: Gold-coated Janus particle, biotin-PEG-thiol 
functionalization, APTES silanization, BSA incubation, and streptavidin incubation. 
When evaluating the success of these functionalization processes, we measured both 
particle size and particle concentration. We expected particle size to increase as we 
altered the particle surface, and indeed, we did observe that trend. Figure 21A shows that 
over the course of the entire conjugation process, particle size did increase from its 
original diameter (approximately 300 nm). However, the two different schemes resulting 
in a fully functionalized Janus particle did not produce particles of equivalent sizes; 
Janus-2 particles were greater than Janus-4 particles. This is perhaps due to biotin-PEG-
thiol and being exposed to the acetone involved in APTES silanization. Acetone disrupts 
tertiary bonds in proteins and therefore may have denatured the biotin-PEG thiol, making 
it unable to bind effectively to streptavidin. We also evaluated particle concentration to 
verify that neither a particular conjugation step nor a specific scheme resulted in a 
 89 
decrease in concentration compared to other steps or schemes. As shown in Figure 21B, 
particle concentration during all functionalization schemes remained steady. 
 
Figure 21: Janus Particle Conjugation Characterization. After each step in the 
conjugation process of functionalizing Janus particles, particle size (A) and concentration 
(B) were measured using the TRPS principal with an IZON qNano. Data are represented 
as mean ± SEM; n=3. 
As shown in Figure 22, Janus particles exhibited spatial segregation of proteins. 
When analyze using flow, single hemisphere-functionalized particles exhibited over 98% 
particle functionalization following APTES silanization and nearly 67% functionalization 
of the gold hemisphere. The reason for this lower functionalization is due to the number 
of steps required – incubation of biotin-PEG-thiol, formation of antibody-streptavidin 
constructs, and then final conjugation of the constructs with the biotinylated particle. Any 
inefficiency at any of these three steps would be propagated and increased, overall 
reducing the efficiency of the gold functionalization. Dual functionalization of Janus 
particles resulted in a 58% yield. Confocal microscopy was used to visually validate this 
functionalization and to assess if the two signals were spatially segregated onto their 
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respective hemispheres. Representative images in Figure 22 depict single and dually 
functional particles and show that spatial segregation was achieved using the described 
protocol to functionalize Janus particles. 
 
Figure 22: Janus Particle Functionalization Characterization. Flow cytometry and 
confocal microscopy was used to verify particle multifunctionality and spatial 
segregation of signal. For characterization purposes, FITC-BSA was used to functionalize 
the silica hemisphere and alexa fluor 647 streptavidin was used to functionalize the gold 
hemisphere following biotin-PEG-thiol conjugation. 
5.3.3 Cell Targeting 
The ability of our particles to target T cells was investigated with all particle formulations 
against primary human T cells. Unsurprisingly, all particles that displayed anti-CD3/28 
antibodies targeted significantly more T cells than all other particles, as represented in 
Figure 23A. We found that simply including anti-FR antibody onto particles significantly 
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increased the number of Ovcar-3 cells with bound particles (Figure 23B). Interestingly, 
anti-FR J. particles elicited the greatest Ovcar-3 binding activity, significantly more than 
Janus particles containing both anti-FR antibody and anti-CD3/28 antibodies. It is 
possible that the SA control protein contributes slightly to the increased binding 
measured, as the SA particles did bind to some Ovcar-3 cells (Figure 23B). It is more 
likely that the inclusion of anti-CD3/28 antibodies on the Janus and control uniform 
particles somehow interfered with the binding capability of these particles, either through 
steric hindrance or by discouraging continued Ovcar-3 interaction with the particle. Also, 
since Janus particles have a clear orientation, it is possible that higher doses of Janus 
particles are necessary to reach an identical amount of binding compared to anti-FR J. 
particles. However, despite any reduction in targeting ability due to anti-CD3/28 
antibodies, Figure 23C shows that our particles target significantly more Ovcar-3 cells 
than our control HeyA8 or hDF cells.  
 
Figure 23: Janus Particle Targeting. CD8+ T cells (A), Ovcar-3 (B, C), HeyA8, and 
hDF cells (C) were incubated for 2 hours with all particle formulations. Secondary 
fluorescent staining against the conjugated antibodies was measured using flow 
cytometry to determine the percentage of cells with bound particles. Data are represented 
mean ± SEM; n=6, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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5.3.4 T cell Activation 
Janus particles were found to activate T cells, despite only half the particle displaying T 
cell stimulating molecules, anti-CD3 and anti-CD28 antibodies. CD8+ T cells were 
purified from peripheral blood using EasySep immunomagnetic negative selection 
(STEMCELL Technologies). Cells were activated using all five particle formulations for 
3 hours on an end-over-end spinner and maintained at 37 ⁰C and 5% CO2. CD107a 
expression – a marker for degranulation – was measured using flow cytometry. As shown 
in Figure 24, particles displaying anti-CD3/28 antibodies activated significantly more 
cells than particles without the T cell-stimulating molecules (p<0.05 at least). 
Additionally, while Janus particles did not elicit greater activation than anti-CD3/28 J. 
particles, they did provoke more cells to become activated than uniformly coated uniform 
particles, together these results suggest that segregating the relevant molecules onto a 
single hemisphere promotes T cell activation. 
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Figure 24: T cell Activation from Janus Particles. T cell activation was measured by 
the expression of CD107a. Cells were analyzed for the surface expression of CD107a by 
staining with FITC anti-human CD107a and then measuring the resultant signal using 
flow cytometry. Data are represented as mean ± SEM, n=6; *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
5.3.5 Interactions between Cancer and T cells 
For this work, non-antigen-specific T cell and cancer cell pairs were used to reduce 
spontaneous binding and thus drive cancer cell-T cell interactions using our particle 
treatments. To determine whether T cells and Ovcar-3 cells would form conjugates in the 
presence of our particles, we used confocal microscopy. T cells were labelled with Cell 
Tracker green and Ovcar-3 cells were labelled with Cell Tracker Deep Red. Cells were 
mixed at a 1:1 ratio, treated with particles, and incubated for three hours. All cells were 
allowed to adhere to coverslips coated with Cell Tak and then stained using Cell Mask 
orange to visualize their plasma membranes. Following paraformaldehyde fixation, 
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nuclei were stained with DAPI and mounted onto glass microscope slides. Figure 26 
shows that while some spontaneous binding occurred between T cells and cancer cells, 
the number of T cells per cancer cell and the frequency of conjugation increased when 
cells were treated with particles that targeted both cells types – i.e. uniform and Janus 
particles. However, we observed that Janus particles elicited far more binding events than 
did uniformly functionalized particles, most likely due to the segregation and therefore 
concentration of targeting molecules on each particle hemisphere. These results show that 
our Janus particle treatment prompts T cell-cancer cell interactions and hence is likely to 
increase cancer cell death. Given the short time frame examined, this crosslinking assay 




Figure 25: Janus Particles cause significant T cell - cancer cell binding. Janus 
particles facilitated T cell binding to cancer cells, as shown in this representative image. 
T cells or clusters of T cells are indicated with white arrows. Scale bar = 30 μm. 
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Figure 26: Janus Particles exhibit high cellular crosslinking. To determine T cell – 
cancer cell binding, cancer cells, CD8+ T cells, and particles were incubated together for 
8 hours. Pre-incubation, cancer cells were labeled with red fluorescent stain and T cells 
with green fluorescent stain. Post-incubation, cell conjugates were labeled with Hoechst 
and orange cell mask plasma membrane stain. Representative images of Janus, uniform, 
and anti-CD3/28 J. particles, and a no particle control condition, are shown. 
5.3.6 Cytotoxicity 
To better understand how T cell – cancer cell crosslinking (Figure 26) due to our particle 
treatments may lead to cancer cell death, cytotoxicity was assessed using a live/dead 
staining procedure with calcein AM and ethidium homodimer-1. Briefly, cancer cells 
were plated in either 24-well or 48-well plates and allowed to reach homeostasis 
overnight. An equivalent number of CD8+ T cells were treated with each particle 
condition added to the cancer cell culture. As shown in Figure 27A, Janus particles 
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elicited the greatest amount of cytotoxicity, significantly more than both uniform 
(p<0.001) and anti-CD3/28 J. particles (p<0.05). Unexpectedly, anti-CD3/28 J. particles 
also caused significantly greater cytotoxicity than uniform particles (p<0.001). This is 
perhaps caused by higher T cell activation using the anti-CD3/28 J. particles, compared 
to uniform particles (Figure 24). These comparisons were evaluated at a 1:1 E:T ratio. 
Differences between groups formulated to elicit T cell activation – Janus, anti-CD3/28 J., 
and uniform particles – increased as the E:T ratio increased (Figure 27B). As the particle 
dose was equivalent at all conditions (i.e. not increasing to reflect increasing T cell 
number), increased cytotoxicity demonstrates that T cell number, or T cell activity to our 
particle treatment, rather than particle dosing, is the limiting factor in the effectiveness of 
using Janus particles as an immunotherapeutic strategy. 
 
Figure 27: Particle-induced Cytotoxicity. (A, B) Cell viability was measured using 
flow cytometry following fluorescent staining with live/dead probes. Data are represented 
as mean ± SEM, n=6; ****p<0.0001. 
 To examine whether cell-specific cytotoxicity could be achieved from Janus 
particles and not from activating T cells in an antigen-specific manner, we evaluated the 
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percentage of untargeted HeyA8 cell death compared to targeted Ovcar-3 cell death. As 
shown in Figure 28, significantly less cytotoxicity was observed using HeyA8 cells. 
Janus particles elicited the greatest difference between the two cell types (p<0.001), 
compared to anti-CD3/28 J. (p<0.01) and uniform particles (p<0.001). This is most likely 
due to the enhanced targeting present on Janus particles in comparison to the other 
particle formulations (Figure 23). As uniform particles contain both T cell activating and 
cancer cell targeting molecules dispersed over the entire particle surface, thereby 
reducing the concentration of each signal, the difference between Ovcar-3 and HeyA8 
cells is reduced. This reduction of signal is also why we observed less cytotoxic death of 
HeyA8 than when treating with Janus particles. Although, theoretically, cancer cell 
specificity is higher on Janus particles than uniform particles, and should thus result in 
higher HeyA8 cytotoxicity measured, anti-CD3/28 antibodies are also dispersed over the 
particle surface which reduces the intensity of this T cell activating signal. As we have 
previously demonstrated that anti-CD3 particles will elicit significant cytotoxicity – 
compared to negative controls – regardless of the targeted cell type (Figure 7), and anti-
CD3/28 J. particles maintain a concentrated T cell activating signal, we hypothesized that 
anti-CD3/28 J. particles would elicit higher cytotoxicity than uniform particles. Indeed, 
compared to uniform particles, anti-CD3/28 particles demonstrated less selectivity.  
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Figure 28: Selectivity of Janus Particles on Cytotoxicity. Ovcar-3 and Hey-A8 cells 
were incubated with an equivalent number of CD8+ T cells and dosed with particles for 
24 hours. Cytotoxicity was measured using a live/dead flow cytometric assay. Data are 
represented as mean ± SEM; n=6, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
5.3.7 Spheroid Characterization 
Next we examined the effect of our Janus particles using an in vitro tumor model, Ovcar-
3 spheroids. Ovcar-3 cells were stained using Cell Tracker Deep Red fluorescent stain 
and then 5 x 10
3
 cells/well were plated in a round bottom, ultra low attachment 96 well 
plate. After 4 days of culturing, spheroids were harvested and mounted onto glass 
microscope slides. Confocal imaging was used to image each spheroid, as shown by the 
representative image in Figure 29. The diameter of each spheroid was measured using 
Zen imaging software (Zeiss). After four days, the average spheroid diameter was 
approximately 1.25 mm. 
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Figure 29: Spheroid Characterization. Ovcar-3 cells were stained with a red 
fluorescent dye and cultured in an ultra low attachment plate for four days before 
imaging with confocal microscopy. Each spheroid was measured using Zen imaging 
software. Scale bar = 200 μm. 
5.3.8 Spheroid Cytotoxicity 
Cytotoxicity of the spheroids was assessed with the same live/dead cytotoxicity kit used 
in our 2D culture flow cytometry experiments. Briefly, spheroids were grown for 4 days 
before getting transferred into a flat bottom 96 well plate and treated simultaneously with 
CD8+ T cells and particles. After 24 hours, spheroids were stained with calcein AM and 
ethidium homodimer-1 and Hoechst before mounting onto glass microscope slides. As 
shown by the representative images in Figure 30, the untreated Ovcar-3 spheroid and T 
cell only-, SA particle- and anti-FR J. particle-treated spheroids exhibited minimal 
cytotoxicity. Anti-CD3/28 J. particles exhibited increased cytotoxicity compared to our 
negative controls and the uniform particle condition. However, the cancer spheroids 
following uniform particle treatment appear to be semi-disassociated, as the spheroid is 
no longer cancer cells strongly adhered to each other, as demonstrated in the previous 
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conditions. Janus particles elicited both the strongest cytotoxicity and the most 
disassociated morphology, suggesting that Janus particles elicit enough cytotoxicity such 
that cell-cell adhesions are disrupted. This altered morphology suggests that the inclusion 
of a targeting molecule allows for deeper penetration of cytotoxicity responses. 
Supporting this hypothesis is that although anti-CD3/28 J. particle elicit greater 
cytotoxicity than uniform particles, the cell death is restricted to the surface of the 
spheroid, according to observations about the images in Figure 29, whereas uniform 




Figure 30: Spheroid Cytotoxicity. Spheroids were evaluated for cytotoxic death using 
fluorescent live/dead stain. Following 24 hour incubation with CD8+ T cells and 
particles, spheroids were stained with calcein AM and ethidium homodimer-1 and 
Hoechst. Representative images are shown of each condition; n=8. Scale bar = 200 μm. 
5.3.9 Dual Cancer Cell Targeting 
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To determine if greater cancer cell death could be elicited by adding an additional cancer 
cell marker, Janus particles functionalized with anti-FR and anti-e-cadherin, two protein 
overexpressed on Ovcar-3 cells, were used to treat cancer cells using a 2D and 3D 
platform. As shown in Figure 31A, the addition of anti-e-cadherin antibody onto the 
particle did not result in greater cancer cell death compared to Janus particles 
functionalized with only anti-folate receptor in the 2D cytotoxicity assay. However, when 
we observe the results of ovarian cancer spheroids treated with Janus particles containing 
one cancer targeting antibody compared to two cancer targeting antibodies, the 
differences are noticeable. While the images shown in Figure 31B are largely 
representative, both conditions provoked highly heterogeneous outcomes. Qualitatively, 
more spheroids were dissociated, semi-dissociated (as in Figure 31B, top) or in large 
pieces (as in Figure 31B, bottom) following treatment with either Janus particle 
formulation. It is not clear whether this spheroid disruption is purely a result of Janus 
particle dosing or if handling during transferring and staining contributed to the observed 
dissociated; however, it is unlikely that harsh handling was restricted to the uniform and 
Janus particle-treated spheroids for all 8 trials. Quantitatively, we observed that Janus 
particles functionalized with two cancer targeting molecules resulted in a concentration 
of dead cells on the outside of the spheroid, whereas the single targeting molecule Janus 
particle elicited cell death that appeared to penetrate into the spheroid. One possible 
explanation of this observation is that folate receptor is upregulated ubiquitously within 
the spheroid because it is involved in metabolism, whereas e-cadherin is an adhesion 
molecule and expressed non-uniformly across tumor spheroids(237). As the flow 
cytometric assay did not reveal any cytotoxicity differences between the two Janus 
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particle formulations, it is possible that any differences we observe in the spheroid are 
exclusive to 3D culture due to the spheroid architecture or that while these two particles 
direct CD8+ T cell cytotoxic responses in different ways, both result in the same amount 
of cancer cell death. 
 
Figure 31: Additional Targeting on Janus Particle does not increase Cytotoxicity. 
Janus particles displaying both anti-FR and anti-e-cadherin antibodies to target Ovcar-3 
cells were incubuated with Ovcar-3 cells using 2D (A) and 3D (B) culture systems. In 
both cases, cells were dosed with particles and CD8+ T cells for 24 hours and then 
stained with live/dead labels. (A) Cells were then measured for cytotoxicity using flow 
cytometry. Data is represented as mean ± SEM; n=6, ****p<0.0001. (B) Spheroids were 
additionally stained with Hoechst and mounted onto glass slides for microscopy. 
Representative images are shown; n=8. 
 Although the inclusion of a second cancer-targeting molecule onto our particle 
platform did not increase cytotoxicity of the targeted cancer cells, we were interested in 
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the effect on non-targeted cells. As shown in Figure 32, both Janus particle formulations 
elicited significantly lower cytotoxicity in the non-targeted HeyA8 cells, in comparison to 
the targeted Ovcar-3 cells. Interestingly, Janus particles that were functionalized with 
anti-e-cadherin antibody in addition to anti-FR antibody decreased the percentage of 
HeyA8 cytotoxicity produced as a response to Janus particle treatment (p<0.05). ). This 
result suggests the second targeting antibody increases the cancer specificity of treatment, 
either as a result of decreased non-specific binding or due to less particle binding to cells 
with low expression of the targeted marker. Theoretically, the inclusion of a second 
antibody shouldn’t have a significant effect on the amount of non-specific binding so it’s 
more likely that fewer particles bind to non-target cells. In the broader context, this effect 
indicates that the specificity of current cancer cell targeting may be improved by 
targeting additional antigens or that non-TAA may even be used to target cancer cells 




Figure 32: Dual-Cancer targeting Decreases Non-Target Cell Cytotoxicity. Janus 
particles displaying both anti-FR and anti-e-cadherin antibodies to target Ovcar-3 cells 
were incubated with Ovcar-e and HeyA8 cells to measure specificity of cell cytotoxicity. 
Cytotoxicity was determined using a live/dead flow cytometric assay. Data are 
represented as mean ± SEM; n=6, *p<0.05, ****p<0.0001. 
5.3.10 T cell Infiltration 
In order to study immune cell infiltration as a result of Janus particle treatment, green 
fluorescent CD8+ T cells and Janus particles were added simultaneously to cancer 
spheroids and cultured for 24 hours. As shown in Figure 33, T cells (green) remained 
mostly on the surface of the spheroid, although some infiltration into the spheroid was 
observed. Following quantification, we found that Janus particle-activated T cells 
infiltrated spheroids significantly more, and that the presence of cancer targeting 
molecule(s) further increased this infiltration. This indicates that both T cell activation 
and cancer cell targeting improve T cell infiltration into tumor spheroids. 
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Figure 33: T cell Infiltration following Janus Particle Treatment. Representative 
image of cancer spheroid treated with Janus particles and CD8+ T cells. Prior to spheroid 
formation, ovcar-3 cells were labelled with red fluorescent stain. T cells were 
fluorescently labeled green before dosing spheroids. Following 24 hour incubation, dead 
cells and nuclei were stained yellow and blue, respectively. Scale bar = 200 μm. 
5.3.11 In vivo toxicity following treatment with Janus particles 
To determine the in vivo response following Janus particle treatment, Janus particles were 
designed to target carcinoembryonic antigen (CEA), an antigen present usually during 
embryonic development or by cancerous cells, and injected i.v. into healthy BALB\c 
mice. Thus, we could examine baseline effects of our particle treatment, i.e. untargeted 
biodistribution and the potential for systemic toxicity. As Janus particles present a dense 
concentration of activating molecules, as discussed in CHAPTER 3, toxicity is a 
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possibility that must be explored. As shown in Figure 34, following Janus or isotype 
control particles, mice were evaluated after 1 hour, 4 hours, or 24 hours. T cell activity 
was also evaluated at 72 hours following a half-dose of particles. 
 
Figure 34: In vivo dosing reginmen. Mice were injected with either Janus or isotype 
control particles (2.5 μg anti-CD3/28 per mouse). At each time point, mice were 
euthanized, and relevant organs were harvested and serum was collected. 
 We evaluated toxicity by measuring the serum concentrations of inflammatory 
cytokines at each time point following treatment. Both Janus and controls particles 
showed elevated serum levels of TNF-α and IL-6, one hour post-injection (Figure 35). 
IL-1β, IL-2, IL-4 and INF-γ were neither detectable at this time point nor at any time 
point assessed. Additionally, TNF-α and IL-6 were no longer detectable after 4 hours. 
Broadly, this indicates that systemic toxicity is not occurring and further that Janus 
particles elicit no more toxicity than control particles. The elevation in TNF-α and IL-6 at 
one hour could be due to macrophage activation. Both cytokines are secreted by 
macrophages, professional phagocytes, and might have been elevated as macrophages 
engulfed the injected particles. 
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Figure 35: Serum cytokine profile. BALB\c mice were dosed as described above and 
their serum collected. Luminex was used to determine systemic toxicity by measuring 
various inflammatory cytokine concentrations. Data are mean ± SD; n=1 (PBS), n=4 
(Janus and control particles). 
5.3.12 In vivo biodistribution 
To visualize the kinetics of particle trafficking in mice, infrared fluorescent imaging was 
performed using alexa fluor 667 anti-mouse CEA conjugated to Janus particles. Images 
taken after 4 hours are shown in Error! Reference source not found., and show a 
lightly higher particle uptake by the liver and kidney in the Janus particle group, 
compared to the control particles or the PBS group. No differences between groups were 
observed after 1 hour or 24 hours (as shown in Appendix A). Notably, very little particle 
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uptake is measured in the spleen while the highest particle signals were measured in the 
lung, liver, and kidney. This is perhaps an indication that particles are not reaching the 
spleen and are instead being readily filtered from the blood by the lungs, liver and 
kidney. 
 
Figure 36: Biodistribution of particles after four hours. BALB\c mice were injected 
i.v. with Janus or control particles, or PBS. Infrared images of harvested organs were 
taken to measure particle trafficking. Data = mean ± SD; n = 1 (PBS), n = 4 (Janus and 
control particles). 
5.3.13 Splenic T cell activation following Janus particle treatment 
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As systemic toxicity was not observed (Figure 35) and particles did not locate to the 
spleen (Figure 36), it was necessary to determine the impact Janus particles had on T cell 
functionality and activation. Splenocytes were stained to identify CD4+ and CD8+ T cell 
subsets and then to measure the percentage of these cells that expressed CD69, a marker 
of activation. This assay was performed at 24 hours (as shown in ) and 72 hours (XYZ). 
At both time points, no significant differences between conditions were observed. This 
suggests that although Janus particles present anti-CD3 and anti-CD28 antibodies, splenic 
T cells exhibit the same amount of activation as isotype control particles. The mechanism 
behind this result is likely multi-fold: the dose may be too low to elicit an activation 
response in vivo, the particles may not have reached the spleen to activate T cells, or 
some combination of both explanations. Additional studies investigating particle dose, 
markers of activated T cells in peripheral blood, or peritoneal delivery of particles should 
give additional insight about how Janus particles may be used as an immunotherapeutic 
strategy for cancer treatment. 
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Figure 37: Splenic T cell profile. (A, B) Mice were dosed as previously described and 
splenic T cell activation was assessed in CD4+ and CD8+ T cell subsets. Data = mean ± 
SD; n = 4. 
5.4 Discussion 
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The tumor spheroid model presented here provides an in vitro model of an ovarian 
cancer tumor. 2D cell culture formats lack the significant cell-cell and cell-matrix 
interactions present in in vivo geometries and further force cells into unnatural 
morphologies(238-241). 3D cell spheroids provide a more accurate representation of cell 
microenvironment, which allows the modeling of multicellular 3D architecture and 
function of tissues, including extracellular matrix deposition, physiological barriers, and 
representative in vivo protein expression(239, 242). Cancer spheroids are especially 
relevant in ovarian cancer contexts, as spheroids best model nonvascularized tumors 
present in epithelial ovarian cancer. Cell spheroids, thus, may act as in vitro tumor 
analogs. Obviously, the spheroids used in the work presented are limited – they contain 
only one cell type and we used an immortalized ovarian cancer cell line. Nonetheless, 
through the use of this spheroid model, we were able to examine not only the extent but 
also location of cytotoxicity elicited from our particle-activated T cells. This is 
meaningful as it gives context to our 2D cytotoxicity results (Figure 27). For example 
anti-CD3/28 J. particles elicited greater cytotoxicity in 2D and 3D culture compared to 
uniform particles. However, the 3D spheroid culture system revealed that this 
cytotoxicity is only on the outside of the spheroid (Figure 30). This is most likely 
because, as there was little to no T cell – cancer cell binding observed following anti-
CD3/28 J. particle treatment (Figure 26), activated CD8+ T cells released cytolytic 
granules simply within the tissue culture well, creating a lytic bath that caused cell death 
on the outermost layer of the spheroid. Additionally, the spheroid results in Figure 30 
show the effectiveness of uniform particles as a cancer immunotherapy; despite the 
decreased cytotoxicity in 2D culture (Figure 27), the treated spheroid was semi-
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disassociated, most likely due to the T cell-cancer cell interactions that occurred (Figure 
26). This line of reasoning also explains why Janus particles were superior at eliciting the 
highest cytotoxicity levels using 2D and 3D in vitro culture systems. Because Janus 
particles displayed an entire hemisphere of densely packed anti-CD3/28 antibodies, T 
cells were strongly activated, as they were following anti-CD3/28 J. particles (Figure 24). 
Therefore, regardless of targeting, there would inevitably be some cancer cell 
cytotoxicity, as described previously about anti-CD3/28 J. particles. The other 
hemisphere of the Janus particle was densely packed with anti-FR antibody (and also 
anti-e-cadherin antibody for the second Janus particle), resulting in a high degree of 
binding, specifically to Ovcar-3 cells (Figure 23). This dual targeting resulted in far 
greater T cell – cancer cell crosslinking than any other particle formulation; showing both 
greater numbers of T cells bound, and more cancer cells with bound T cells (Figure 25 
and Figure 26). Therefore, treating cancer cells with Janus particles and T cells resulted 
in activated CD8+ T cells that were crosslinked to targeted cancer cells, causing high 
cytotoxicity in both 2D and 3D cell cuture, and further spheroid disassociated in cancer 
spheroid models. 
5.5 Conclusions 
In conclusion, the work presented here demonstrates the first use of Janus particles to 
physically crosslink effector and target cell, while simultaneously activating T cells in a 
nonspecific manner. The resultant crosslinking and activation produces significantly 
greater cytotoxicity in both 2D and 3D cancer cell culture systems than uniformly coated 
particles. Janus particles, therefore, should be considered as a potential therapeutic 
platform for cancer immunotherapy. Whereas bispecific antibodies involve complicated 
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and expensive manufacturing processes, Janus particles allow for target cell specificity 
with the ease of non-specific immune cell activation using a platform that may be easily 
modified. While Janus particle treatment did not translate smoothly into splenic T cell 
activation in vivo, the lack of system wide toxicity is promising. Additional studies will 
help clarify an appropriate dose and delivery method. 
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CHAPTER 6. CONCLUSIONS 
6.1 Overall Summary 
In this presented work, we expand our knowledge of how particles can serve to both bind 
cancer cells and coordinate activated T cells responses. The mechanics behind non-
antigen specific T cell activation by investigating how particle size, antibody 
functionalization density, and activating signal elicit the greatest degree of T cell 
response all informed the particle design. We utilized this information to design Janus 
particles that selectively kill cancer cells while activating resident cytotoxic T cells in a 
non-specific manner. 
 In Specific Aim 1, we demonstrated the effect of particle size, molecular density, 
and activating molecule on T cell activation and cytotoxicity. 300 nm particles, compared 
to 1 μm and 3 μm, and approximately 50% anti-CD3 antibody surface coverage results in 
increased GrB release. T cell activation and cytotoxicity depends on the activating 
molecule(s) as well: cytotoxicity studies showed that anti-CD3 particles were more 
effective than soluble antibody alone and demonstrated that immune cell proximity to 
cancer cells was responsible for cancer cell death. Including anti-CD28 antibody for co-
stimultation resulted in increased T cell activation that was characterized by more robust 
immune synapse formation, cytoskeletal remodeling, and cell softening. The significance 
of this work lies in the establishment that anti-CD3/28 particles can non-specifically 
activate T cells to the extent that cancer cell are killed, although in an untargeted manner. 
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 In Specific Aim 2, we engineered Janus particles to display T cell-activating 
molecules on one hemisphere and cancer targeting antibodies on the other hemisphere 
and explored the effect of this particle to elicit cancer cell death using a 2D and 3D 
ovarian cancer model. We demonstrate that this particle is capable of activating T cells 
and targeting both CD8+ T cells and Ovcar-3 cells over other cell lines, including ovarian 
cancer cell lines. We hypothesized that this specific targeting would physically crosslink 
immune cells and Ovcar-3 cells, and indeed, we observed that Janus particles over other 
particles tested increased T cell binding to cancer cells and thus, also enhanced 
cytotoxicity over other tested particles. We show for the first time that Janus particles are 
superior to uniformly coated particles when directing a non-specific T cell activation 
response to a specific cancer cell. Additionally, we demonstrate that while adding a 
second cancer targeting molecule does not increase cytotoxicity of the targeted cells, it 
does reduce cytotoxicity of non-targeted cells. An exploratory in vivo study substantiated 
the safety of our Janus particle approach. Taken together, these results suggest that Janus 
particles are an effective cancer immunotherapy platform. The significance of this work 
lies in demonstrating the importance of segregating T cell-activating and cancer cell-
targeting signals and the improved specific anti-cancer outcomes. 
These results also highlight the need for additional selectivity studies in which 
cancer cells do not display well established markers that may be used for targeting 
purposes. Antigen specific T cell activation should also be studied in comparison to non-
specific activation, to ensure that off target effects are minimal; it’s possible that the 
immune-activating hemisphere of the Janus particle contains molecules for both specific 
and non-specific T cell activation. Further activation studies using NK cells are also 
 118 
possible and could be an interesting approach to leverage the innate immune system 
against specific cancer cells. The Janus particle platform should also be tested against 
tumors in an animal model, so that we can evaluate the effectiveness of this novel 
approach against cancer. Additional in vivo studies would aid in our understanding of 
how immunosuppressive cues within the tumor microenvironment affect Janus particle 
performance.  
 The work presented herein contains the first studies in which Janus particles are 
used to physically bind and bring together effector immune cells and target cancerous 
cells. While bispecific antibodies accomplish similar actions, our Janus particle treatment 
combines this strategy with multivalency, which can be leveraged to present not only 
strong immune activating signals but also multiple cancer targeting molecules, leading to 
strong cytotoxic T cell responses against specific cancer cells. Janus particles offer a 
unique strategy in which we can tune immune activation to limit overstimulation, elicit 
cancer-specific death in a non-antigen specific manner, and easily alter cancer targeting 
molecules to accommodate cancer and disease heterogeneity; the multifunctionality and 
modularity inherent to particles are not found with single molecule treatments. This novel 
and promising approach to cancer immunotherapy should be developed and studied 
further. The results from this work can also be applied to the greater biomaterial and 
immunoengineering fields to not only better understand biophysical design parameters 
for the appropriate outcome but also to positively contribute towards better disease 




A. Supplemental for in vivo biodistribution study 
6.1.1 Biodistribution after 1 hour 
 
Figure 38: Particle or vehicle biodistribution after 1 hour. 
6.1.2 Biodistribution after 24 hours 
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